# The Therapy Intensity Level scale for traumatic brain injury: clinimetric assessment on neuro-monitored patients across 52 European intensive care units

4

Shubhayu Bhattacharyay<sup>1,2,\*</sup>, Erta Beqiri<sup>3</sup>, Patrick Zuercher<sup>4</sup>, Lindsay Wilson<sup>5</sup>,
 Ewout W Steyerberg<sup>6</sup>, David W Nelson<sup>7</sup>, Andrew I R Maas<sup>8,9</sup>, David K Menon<sup>1</sup>, Ari
 Ercole<sup>1,10</sup>, and the CENTER-TBI investigators and participants<sup>†</sup>

- 8
- <sup>9</sup> <sup>1</sup>Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.
- <sup>2</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, United
   Kingdom.
- <sup>12</sup> <sup>3</sup>Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge,
- 13 Cambridge, United Kingdom.
- <sup>4</sup>Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University
- 15 of Bern, Switzerland.
- <sup>5</sup>Division of Psychology, University of Stirling, Stirling, United Kingdom.
- <sup>6</sup>Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden,
- 18 The Netherlands.
- <sup>19</sup> <sup>7</sup>Department of Physiology and Pharmacology, Section for Perioperative Medicine and
- 20 Intensive Care, Karolinska Institutet, Stockholm, Sweden.
- <sup>8</sup>Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.
- <sup>9</sup>Department of Translational Neuroscience, Faculty of Medicine and Health Science,
- 23 University of Antwerp, Antwerp, Belgium.
- <sup>10</sup>Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.
- 26 \*Corresponding author: <u>sb2406@cam.ac.uk</u> (SB)
- <sup>27</sup> <sup>†</sup>A full list of the CENTER-TBI investigators and participants are listed after the
- 28 acknowledgements.
- 29
- 30 **Running title:** Assessment of the Therapy Intensity Level scale
- 31 **Keywords:** traumatic brain injury, therapy intensity level, intracranial pressure, intensive
- 32 care unit, clinimetrics
- 33

Shubhayu Bhattacharyay	<u>sb2406@cam.ac.uk</u> +44 (0)1223 217889 Division of Anaesthesia, University of Cambridge,
	Box 93, Addenbrooke's Hospital,
	Hills Road, Cambridge CB2 0QQ, United Kingdom
Erta Beqiri	<u>vb391@cam.ac.uk</u> +44 (0)7912 138171
	Brain Physics Lab, Division of Neurosurgery, University of Cambridge, Box 167, Level A4, A Block, Addenbrooke's Hospital,
	Hills Road,
	Cambridge CB2 0QQ, United Kingdom
Patrick Zuercher	patrick.zuercher@insel.ch +41 31 664 15 77
	Department of Intensive Care Medicine, Inselspital,

	Bern University Hospital, University of Bern,
	Freiburgstrasse 18,
	CH-3010 Bern, Switzerland
Lindsay Wilson	I.wilson@stir.ac.uk
-	+44 (0)1786 473171
	Division of Psychology,
	Faculty of Natural Sciences,
	University of Stirling,
	Stirling FK9 4LA, United Kingdom
Ewout W Steyerberg	e.w.steyerberg@lumc.nl
	+31 (0)71 5269700
	Dept of Biomedical Data Sciences, Leiden University Medical Center,
	Leiden, The Netherlands
David W Nelson	david.nelson@regionstockholm.se
	+46 812379168
	Function Perioperative medicine and Intensive Care (PMI),
	Karolinska University Hospital, Solna,
	17176 Stockholm, Sweden
Andrew I R Maas	andrew.maas@uza.be
	+32 38214632
	Department of Neurosurgery, Antwerp University Hospital,
	Drie Eikenstraat 655, 2650 Edegem, Belgium
David K Menon	dkm13@cam.ac.uk
	+44 (0)1223 217889
	Division of Anaesthesia, University of Cambridge,
	Box 93, Addenbrooke's Hospital,
	Hills Road,
	Cambridge CB2 0QQ, United Kingdom
Ari Ercole	ae105@cam.ac.uk
	+44 (0)1223 217889
	Division of Anaesthesia, University of Cambridge,
	Box 93, Addenbrooke's Hospital,
	Hills Road,
	Cambridge CB2 0QQ, United Kingdom

## 35 **ABSTRACT**

36

Intracranial pressure (ICP) data from traumatic brain injury (TBI) patients in the intensive 37 care unit (ICU) cannot be interpreted appropriately without accounting for the effect of 38 administered therapy intensity level (TIL) on ICP. A 15-point scale was originally proposed 39 in 1987 to quantify the hourly intensity of ICP-targeted treatment. This scale was 40 subsequently modified – through expert consensus – during the development of TBI 41 Common Data Elements to address statistical limitations and improve usability. The 42 43 latest, 38-point scale (hereafter referred to as TIL) permits integrated scoring for a 24hour period and has a five-category, condensed version (TIL<sup>(Basic)</sup>) based on gualitative 44 assessment. Here, we perform a total- and component-score analysis of TIL and TIL<sup>(Basic)</sup> 45 to: (1) validate the scales across the wide variation in contemporary ICP management, 46 47 (2) compare their performance against that of predecessors, and (3) derive guidelines for proper scale use. From the observational Collaborative European NeuroTrauma 48 Effectiveness Research in TBI (CENTER-TBI) study, we extract clinical data from a 49 prospective cohort of ICP-monitored TBI patients (n=873) from 52 ICUs across 19 50 countries. We calculate daily TIL and TIL<sup>(Basic)</sup> scores (TIL<sub>24</sub> and TIL<sup>(Basic)</sup><sub>24</sub>, respectively) 51 from each patient's first week of ICU stay. We also calculate summary TIL and TIL<sup>(Basic)</sup> 52 scores by taking the first-week maximum (TIL<sub>max</sub> and TIL<sup>(Basic)</sup><sub>max</sub>) and first-week median 53 (TIL<sub>median</sub> and TIL<sup>(Basic)</sup><sub>median</sub>) of TIL<sub>24</sub> and TIL<sup>(Basic)</sup><sub>24</sub> scores for each patient. We find that, 54 55 across all measures of construct and criterion validity, the latest TIL scale performs 56 significantly greater than or similarly to all alternative scales (including TIL<sup>(Basic)</sup>) and integrates the widest range of modern ICP treatments. TILmedian outperforms both TILmax 57 and summarised ICP values in detecting refractory intracranial hypertension (RICH) 58 during ICU stay. The RICH detection thresholds which maximise the sum of sensitivity 59 and specificity are TIL<sub>median</sub> ≥7.5 and TIL<sub>max</sub> ≥14. The TIL<sub>24</sub> threshold which maximises the 60 sum of sensitivity and specificity in the detection of surgical ICP control is  $TIL_{24} \ge 9$ . The 61 62 median scores of each TIL component therapy over increasing TIL<sub>24</sub> reflect a credible staircase approach to treatment intensity escalation, from head positioning to surgical ICP 63 control, as well as considerable variability in the use of cerebrospinal fluid drainage and 64 decompressive craniectomy. Since TIL(Basic)max suffers from a strong statistical ceiling 65 effect and only covers 17% (95% CI: 16–18%) of the information in TIL<sub>max</sub>, TIL<sup>(Basic)</sup> should 66 not be used instead of TIL for rating maximum treatment intensity. TIL<sup>(Basic)</sup><sub>24</sub> and 67 68 TIL<sup>(Basic)</sup><sub>median</sub> can be suitable replacements for TIL<sub>24</sub> and TIL<sub>median</sub>, respectively (with up to 33% [95% CI: 31-35%] information coverage) when TIL assessment is infeasible. 69 Accordingly, we derive numerical ranges for categorising TIL<sub>24</sub> scores into TIL<sup>(Basic)</sup><sub>24</sub> 70 71 scores. In conclusion, our results validate TIL across a spectrum of ICP management and 72 monitoring approaches. TIL is a more sensitive surrogate for pathophysiology than ICP and thus can be considered an intermediate outcome after TBI. 73

#### 74 MAIN TEXT

75

#### 76 Introduction

77

Elevated intracranial pressure (ICP) following traumatic brain injury (TBI) may impede the 78 potential recovery of injured brain tissue and damage initially unaffected brain regions.<sup>1</sup> 79 Therefore, for TBI patients admitted to the intensive care unit (ICU), clinicians often 80 monitor ICP and apply a wide range of ICP-reducing treatments.<sup>2</sup> The selective use of 81 these treatments typically follows a staircase approach, in which therapeutic intensity -82 83 defined by the risk and complexity of each treatment – is incrementally escalated until adequate ICP control is achieved.<sup>3–5</sup> Thus, therapeutic intensity must be considered when 84 interpreting ICP. Even if two TBI patients have comparable ICP values, a difference in the 85 intensity of their ICP-directed therapies likely indicates a difference in pathophysiological 86 87 severity.

88

89 Several versions of the Therapy Intensity Level (TIL) scale have been developed to rate and compare the overall intensity of ICP management amongst TBI patients. TIL scales 90 assign a relative intensity score to each ICP-targeting therapy and return either the sum 91 92 or the maximum value of the scores of simultaneously applied therapies. In 1987, Maset et al. produced the original, 15-point TIL scale (TIL<sup>(1987)</sup>) to be assessed once every four 93 hours.<sup>6</sup> In 2006, Shore et al. published the 38-point Paediatric Intensity Level of Therapy 94 (PILOT) scale,<sup>7</sup> revising TIL<sup>(1987)</sup> to: (1) represent updated paediatric TBI management 95 practices, (2) have a more practical, daily assessment frequency, and (3) resolve a 96 statistical ceiling effect. In 2011, the interagency TBI Common Data Elements (CDE) 97 98 scheme developed the most recent, 38-point TIL scale (hereafter referred to as TIL) as well as a condensed, five-category TIL<sup>(Basic)</sup> scale through expert consensus.<sup>8</sup> The TIL 99 scale revised PILOT to integrate additional ICP-directed therapies and to be applicable 100 to adult TBI management. Moreover, TIL<sup>(Basic)</sup> was proposed as a simple, categorical 101 measure to use when full TIL assessment would be infeasible. Since Zuercher et al. 102 reported the validity and reliability of TIL in a two-centre cohort (*n*=31) in 2016,<sup>9</sup> the scale 103 has become a popular research metric for quantifying ICP treatment intensity.<sup>10–13</sup> 104

105

However, several critical questions regarding TIL remain unanswered. It is uncertain 106 whether the validity of TIL, reported in a relatively small population, can be generalised 107 across the wide variation of ICP management, monitoring, and data acquisition (i.e., 108 intermittent chart recording or high-resolution storage<sup>14</sup>) strategies practised in 109 contemporary intensive care.<sup>11,12,15,16</sup> Furthermore, the scoring configuration of TIL has 110 never been tested against alternatives (e.g., TIL<sup>(1987)</sup> and PILOT), and the relative 111 contribution of TIL's component therapies towards the total score is unknown. It is unclear 112 how TIL<sup>(Basic)</sup> numerically relates to TIL and if the former captures the essential information 113 114 of the latter. In this work, we aimed to answer these questions by performing a 115 comprehensive assessment of TIL on a large, contemporary population of ICP-monitored TBI patients across European ICUs. 116

117

## 118 Materials and Methods

#### 119

## 120 Therapy intensity level (TIL) and alternative scales

121

TIL refers to the 38-point scale developed by the CDE scheme for TBI.<sup>8</sup> The domain or 122 construct (i.e., targeted concept of a scale) of TIL is the therapeutic intensity of ICP 123 management. The TIL scale has twelve items, each representing a distinct ICP-targeting 124 treatment from one of eight modalities, as defined in Table 1. TIL was developed by an 125 international expert panel which discussed: (1) the relevant ICP-treatment modalities of 126 modern intensive care, (2) the relative risk and efficacy of individual therapies to derive 127 scores, and (3) practical and statistical limitations of previous TIL scores.<sup>8</sup> In this way, TIL 128 is a formative measurement model, in which the construct (i.e., ICP treatment intensity) 129 is not unidimensional but rather defined by the combination of items (i.e., ICP-targeting 130 treatments).<sup>17</sup> TIL was shown to have high interrater and intrarater reliability by Zuercher 131 et al.<sup>9</sup> If a decompressive craniectomy was performed as a last resort for refractory 132 intracranial hypertension, its score was included in the day of the operation and in every 133 subsequent day of ICU stay. TIL scores can be calculated as frequently as clinically 134 desired. For our analysis, we calculated the following TIL scores from the first seven days 135 of ICU stay: 136

- 137 138
- TIL<sub>24</sub>, the daily TIL score based on the sum of the highest scores per item per calendar day,
- TIL<sub>max</sub>, the maximum TIL<sub>24</sub> over the first week of a patient's ICU stay,
- TIL<sub>median</sub>, the median TIL<sub>24</sub> over the first week of a patient's ICU stay.
- 140 141

139

We also calculated scores from four other therapeutic intensity scales to compare with 142 TIL scores. The 21-point, unweighted TIL (uwTIL) scale replaces each sub-item score in 143 TIL with its ascending rank index (i.e., 1, 2, 3, ...) within each item (Table 1). The five-144 category TIL<sup>(Basic)</sup> was also developed by the CDE scheme for TBI and takes the 145 maximum score, from zero (i.e., no ICP-related intervention) to four, amongst all included 146 sub-items over the calendar day.<sup>8</sup> We adapted the 38-point PILOT<sup>7</sup> and 15-point TIL<sup>(1987)</sup> 147 scales<sup>6</sup> with minor adjustments to fit the items of TIL with a daily assessment frequency. 148 PILOT was also shown to have high interrater and intrarater reliability by Shore et al.<sup>7</sup> For 149 the four alternative scales, daily (i.e., uwTIL<sub>24</sub>, TIL<sup>(Basic)</sup><sub>24</sub>, PILOT<sub>24</sub>, and TIL<sup>(1987)</sup><sub>24</sub>), maximum (i.e., uwTIL<sub>max</sub>, TIL<sup>(Basic)</sup><sub>max</sub>, PILOT<sub>max</sub>, and TIL<sup>(1987)</sup><sub>max</sub>), and median (i.e., 150 151 uwTIL<sub>median</sub>, TIL<sup>(Basic)</sup><sub>median</sub>, PILOT<sub>median</sub>, and TIL<sup>(1987)</sup><sub>median</sub>) scores were calculated in the 152 same way as TIL<sub>24</sub>, TIL<sub>max</sub>, and TIL<sub>median</sub>, respectively. 153

154

## 155 Study design and populations

156

Our study population was prospectively recruited for the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) core and high-resolution studies. CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65 medical centres across 18 European countries and Israel. Patients were recruited between 19 December 2014 and 17 December 2017 if they met the following criteria: (1) presentation within 24 hours of a TBI, (2) clinical indication for a CT scan, and (3) no severe pre-existing neurological disorder. In accordance with

relevant laws of the European Union and the local country, ethical approval was obtained
 for each site, and written informed consent by the patient or legal representative was
 documented electronically. The list of sites, ethical committees, approval numbers, and
 approval dates can be found online: <a href="https://www.center-tbi.eu/project/ethical-approval">https://www.center-tbi.eu/project/ethical-approval</a>.
 The project objectives and design of CENTER-TBI have been described in detail
 previously.<sup>18,19</sup>

170

In this work, we applied the following inclusion criteria in addition to those of CENTER TBI (Fig. 1): (1) primary admission to the ICU, (2) at least 16 years old at ICU admission,
 (3) invasive ICP monitoring, (4) no decision to withdraw life-sustaining therapies (WLST)

- on the first day of ICU stay, and (5) daily assessment of TIL.
- 175

For our sub-studies evaluating the association between TIL and ICP-derived values, we created two sub-populations based on the type of ICP values available. Patients with endhour ICP (ICP<sub>EH</sub>) values, which were recorded by clinicians at the end of every other hour, constituted the TIL-ICP<sub>EH</sub> sub-population. Patients with high-resolution ICP values (ICP<sub>HR</sub>), which were automatically stored with monitoring software, constituted the TIL-ICP<sub>HR</sub> sub-population. All patients in the TIL-ICP<sub>HR</sub> sub-population were also members of the TIL-ICP<sub>EH</sub> sub-population (Fig. 1).

183

## 184 Data collection

185

Data for the CENTER-TBI study was collected through the QuesGen electronic case report form system (QuesGen Systems Inc, Burlingame, CA, USA) hosted on the International Neuroinformatics Coordinating Facility (INCF) platform (INCF, Stockholm, Sweden). All data for the validation populations, except high-resolution signals, were extracted from the CENTER-TBI core study<sup>19</sup> (v3.0, ICU stratum) using Opal database software.<sup>20</sup>

192

## 193 ICP management data for TIL calculation

194

Since TIL<sub>24</sub> was found to be a reliable summary of hourly TIL,<sup>9</sup> clinical data pertinent to the component items of TIL (i.e., ICP-guided treatments, Table 1) were recorded daily through the first week of ICU stay. We extracted all daily TIL item values for our population, and calculated TIL<sub>24</sub>, uwTIL<sub>24</sub>, TIL<sup>(Basic)</sup><sub>24</sub>, PILOT<sub>24</sub>, and TIL<sup>(1987)</sup><sub>24</sub> as defined in Table 1. For patients who underwent WLST after the first day of ICU stay, we only extracted TIL item information from before the documented date of WLST decision.

201

## 202 ICP<sub>EH</sub> and related values

203

End-hour ICP (ICP<sub>EH</sub>), systolic blood pressure (SBP<sub>EH</sub>), and diastolic blood pressure (DBP<sub>EH</sub>) were recorded by clinicians every two hours for the TIL-ICP<sub>EH</sub> sub-population. Mean arterial pressure (MAP<sub>EH</sub>) was calculated as MAP<sub>EH</sub> = (SBP<sub>EH</sub> + 2DBP<sub>EH</sub>)/3, and cerebral perfusion pressure (CPP<sub>EH</sub>) was calculated as CPP<sub>EH</sub> = MAP<sub>EH</sub> – ICP<sub>EH</sub>. From ICP<sub>EH</sub> and CPP<sub>EH</sub>, we calculated the following values:

- ICP<sub>24</sub> or CPP<sub>24</sub>, the mean ICP or CPP value over a calendar day of ICU stay,
- 210 211
- ICP<sub>max</sub> or CPP<sub>min</sub>, the maximum ICP<sub>24</sub> or minimum CPP<sub>24</sub> value over the first week of a patient's ICU stay,
- ICP<sub>median</sub> or CPP<sub>median</sub>, the median ICP<sub>24</sub> or CPP<sub>24</sub> value over the first week of a patient's ICU stay.
- 214

#### 215 ICP<sub>HR</sub> and related values

216

217 High-resolution signals were collected using either ICM+ software (Cambridge Enterprise Ltd, Cambridge, UK; http://icmplus.neurosurg.cam.ac.uk), Moberg CNS monitor (Moberg 218 Research Inc, Ambler, PA, USA; https://www.moberg.com), or both. Blood pressure was 219 obtained through arterial lines connected to pressure transducers. High-resolution ICP 220 (ICP<sub>HR</sub>) was acquired from either an intraparenchymal strain gauge probe (Codman ICP 221 MicroSensor, Codman & Shurtleff Inc, Raynham, MA, USA), a parenchymal fibre optic 222 223 pressure sensor (Camino ICP Monitor, Integra Life Sciences, Plainsboro, NJ, USA; https://www.integralife.com/), or an external ventricular drain. Detailed data collection and 224 pre-processing methods (i.e., artefact cleaning and down-sampling to ten-second 225 averaged time series) applied to high resolution signals in our study have been described 226 227 previously.<sup>21</sup> Ten-second averaged ICP (ICP<sub>HR 10sec</sub>) and CPP (CPP<sub>HR 10sec</sub>) time-series were retrieved for this analysis, and, from ICP<sub>HR 10sec</sub> and CPP<sub>HR 10s</sub>, we calculated 228 ICP<sub>24</sub>/CPP<sub>24</sub>, ICP<sub>max</sub>/CPP<sub>min</sub>, and ICP<sub>median</sub>/CPP<sub>median</sub> as described above. 229

230

#### 231 Physician impressions

232

Attending ICU physicians were asked to record their daily concerns with the patient's ICP 233 and CPP, separately, on a scale from one (not concerned) to ten (most concerned). 234 Moreover, on each patient's ICU discharge summary, physicians were asked to record 235 whether the patient experienced refractory intracranial hypertension during his or her ICU 236 stay. Refractory intracranial hypertension was defined as recurrent, sustained (i.e., of at 237 least ten minutes) increases of ICP above 20 mmHg despite medical ICP management. 238 We extracted the daily ICP/CPP concern ratings and refractory intracranial hypertension 239 impressions which coincided with the ICU stays of our population. 240

241

## 242 Baseline characteristics, prognosis, and outcome

243

We extracted baseline demographic characteristics, Marshall CT classifications,<sup>22</sup> and Glasgow Coma Scale (GCS)<sup>23</sup> scores from ICU admission.<sup>24</sup> We also extracted Glasgow Outcome Scale – Extended (GOSE) functional outcome scores at six months postinjury,<sup>25</sup> with imputation of missing values as previously described.<sup>26</sup> Finally, we extracted ordinal functional outcome prognosis scores, calculated from a tokenised embedding of all available clinical information in the first 24 hours of ICU stay, as described previously.<sup>27</sup>

250

#### 251 Validation

252

We appraised the validity of TIL according to recommendations of best practice from clinimetric literature.<sup>28</sup> Based on the identified domain of TIL, we evaluated the construct and criterion validities of TIL. Our qualitative and quantitative assessments of TIL were performed against those of alternative scoring configurations (Table 1) for comparison.

257

#### 258 Construct validity

259

266

Construct validity is the extent to which a clinical scale matches expectations of associations with parameters within or outside the identified domain. Construct validity is further broken down into convergent validity (i.e., associations with similar constructs), discriminant validity (i.e., associations with divergent constructs), and differentiation by known groups. In this work, statistical associations between study variables were measured with:

- Spearman's correlation coefficients ( $\rho$ ) for static (i.e., measured once) variables,
- repeated measures correlation coefficients  $(r_{rm})^{29}$  interpreted as within-individual strength of association – for longitudinal (i.e., measured over time) variables,
- linear mixed effects regression (LMER) coefficients ( $\beta_{LMER}$ ) of daily scale scores (e.g., TIL<sub>24</sub>) when regressing ICP<sub>24</sub> or CPP<sub>24</sub> on daily scale scores and the day of ICU stay (Day<sub>ICU</sub>), accounting for inter-patient variability with random intercepts. Therefore,  $\beta_{LMER}$  were interpreted as the expected difference in ICP<sub>24</sub> or CPP<sub>24</sub> per unit increase of daily scale score, independent of time since ICU admission or inter-patient variation.
- 275

For convergent validity, we expected therapeutic intensity to correlate at least mildly (i.e., 276  $|\rho| \ge 0.2$ ,  $|r_{rm}| \ge 0.2$ ,  $|\beta_{LMER}| > 0$ ) with markers of injury severity (i.e., baseline GCS and 277 baseline outcome prognoses), functional outcome (i.e., six-month GOSE), clinical 278 concerns of ICP status, and ICP itself. Accordingly, we calculated: (1)  $\rho$  values between 279 280 TIL<sub>max</sub> and GCS, ordinal prognosis scores, GOSE, and ICP<sub>max</sub>, (2)  $\rho$  values between TIL<sub>median</sub> and GCS, ordinal prognosis scores, GOSE, and ICP<sub>median</sub>, (3) r<sub>m</sub> values between 281 TIL<sub>24</sub> and physician concern of ICP and ICP<sub>24</sub>, and (4)  $\beta_{LMER}$  of TIL<sub>24</sub> when regressing 282 283 ICP<sub>24</sub> on Day<sub>ICU</sub> and TIL<sub>24</sub> (i.e., ICP<sub>24</sub>~Day<sub>ICU</sub>+TIL<sub>24</sub>), accounting for inter-patient 284 variability with random intercepts.

285

286 For discriminant validity, we expected therapeutic intensity to be more strongly correlated with ICP and physician concerns of ICP than with CPP and physician concerns of CPP, 287 288 respectively. Even though CPP control through fluid loading or vasopressor therapy is a 289 component modality of TIL (Table 1), we expected TIL to capture ICP management (i.e., 290 the construct) more accurately than CPP management. We compared: (1)  $\rho$  values of TIL<sub>max</sub> vs. CPP<sub>min</sub> to those of TIL<sub>max</sub> vs. ICP<sub>max</sub>, (2)  $\rho$  values of TIL<sub>median</sub> vs. CPP<sub>median</sub> to 291 292 those of TIL<sub>median</sub> vs. ICP<sub>median</sub>, (3) r<sub>m</sub> values of TIL<sub>24</sub> vs. CPP<sub>24</sub> to those of TIL<sub>24</sub> vs. ICP<sub>24</sub>, and (4) the  $\beta_{LMER}$  of TIL<sub>24</sub> when regressing CPP<sub>24</sub>~Day<sub>ICU</sub>+TIL<sub>24</sub> to the  $\beta_{LMER}$  of TIL<sub>24</sub> when 293 regressing ICP<sub>24</sub>~Day<sub>ICU</sub>+TIL<sub>24</sub>. 294

295

For differentiation by known groups, we expected TIL<sub>max</sub> and TIL<sub>median</sub> to effectively discriminate patients who experienced refractory intracranial hypertension during ICU stay from those who did not. We calculated the area under the receiver operating

characteristic curve (AUC), which, in our case, was interpreted as the probability of a randomly selected patient with refractory intracranial hypertension having a higher TIL<sub>max</sub> or TIL<sub>median</sub> score than one without it. We also compared the AUCs of TIL<sub>max</sub> and TIL<sub>median</sub> to ICP<sub>max</sub> and ICP<sub>median</sub> and determined the sensitivity and specificity of refractory intracranial hypertension detection at each threshold of TIL<sub>max</sub> and TIL<sub>median</sub>.

304

#### 305 Criterion validity

306

Criterion (or concurrent) validity is the degree to which there is an association between a 307 308 clinical scale and other scales measuring the same construct, particularly a gold standard assessment. Since there is no extant "gold standard" for assessing ICP management 309 intensity, we tested the concurrent criterion validity of TIL by calculating its associations 310 with its predecessors (i.e., PILOT and TIL<sup>(1987)</sup>), mindful of their limitations as described 311 above. More specifically, we calculated: (1)  $\rho$  values between TIL<sub>max</sub> and prior scale 312 maximum scores (i.e., PILOT<sub>max</sub> and TIL<sup>(1987)</sup><sub>max</sub>), (2)  $\rho$  values between TIL<sub>median</sub> and prior 313 scale median scores (i.e., PILOT<sub>median</sub> and TIL<sup>(1987)</sup><sub>median</sub>), and (3)  $r_{rm}$  between TIL<sub>24</sub> and 314 prior scale daily scores (i.e., PILOT<sub>24</sub> and TIL<sup>(1987)</sup><sub>24</sub>). 315

316

## 317 Component item analysis

318

We evaluated inter-item (i.e., inter-treatment) and adjusted item-total associations of 319 TIL<sub>24</sub>, uwTIL<sub>24</sub>, PILOT<sub>24</sub>, and TIL<sup>(1987)</sup><sub>24</sub> by calculating  $r_m$  values. Item-total correlations 320 were adjusted by subtracting the tested item score from the total score prior to calculating 321 the correlation. We measured Cronbach's alpha ( $\alpha$ ) to assess internal reliability amongst 322 scale items at each day of ICU stay. Moreover, we calculated the median score 323 324 contribution of each item per total  $TIL_{24}$  score. The association between each  $TIL_{24}$  item score and ICP<sub>24</sub>, CPP<sub>24</sub>, physician concern of ICP, and physician concern of CPP was 325 calculated with  $r_m$  values. Finally, we trained LMER models regressing ICP<sub>24</sub> and CPP<sub>24</sub> 326 on all TIL items (with categorical dummy encoding) and Day<sub>ICU</sub> concurrently. The  $\beta_{LMER}$ 327 328 values from these models were interpreted as the average change in ICP<sub>24</sub> or CPP<sub>24</sub> 329 associated with each treatment when accounting for all other ICP-guided treatments, time 330 since ICU admission, and inter-patient variability with random intercepts.

331

## 332 TIL<sup>(Basic)</sup> information coverage

333

We examined the distributions of TIL<sup>(Basic)</sup><sub>24</sub> per TIL<sub>24</sub> and TIL<sub>24</sub> per TIL<sup>(Basic)</sup><sub>24</sub> to derive thresholds for categorising TIL<sub>24</sub> into TIL<sup>(Basic)</sup><sub>24</sub>. We also calculated the information coverage (IC) of TIL<sup>(Basic)</sup> by dividing the mutual information (MI) of TIL<sup>(Basic)</sup> and TIL by the entropy of TIL. IC was calculated with TIL<sup>(Basic)</sup><sub>24</sub> and TIL<sub>24</sub> for days one through seven of ICU stay, with TIL<sup>(Basic)</sup><sub>max</sub> and TIL<sub>max</sub>, and with TIL<sup>(Basic)</sup><sub>median</sub> and TIL<sub>median</sub>.

339

## 340 Statistical analysis

341

#### 342 *Multiple imputation of missing values*

343

Five of the static study variables had missing values for some of the patients in our study: 344 GCS, GOSE, baseline prognosis scores, Marshall CT classifications, and refractory 345 intracranial hypertension status. We assessed the patterns of missingness 346 (Supplementary Fig. S1) and multiply imputed (*m*=100) these variables with independent, 347 stochastic predictive mean matching functions using the *mice* package<sup>30</sup> (v3.9.0) in R 348 349 (v4.2.3). We assumed these variables to be missing-at-random (MAR) (as previously reported on CENTER-TBI data<sup>31</sup>) and supported this assumption by training imputation 350 models on all study measures as well as correlated auxiliary variables (e.g., raised ICP 351 352 during ICU stay).

353

For daily longitudinal study variables, we considered a value to be missing if the patient 354 was still in the ICU and WLST had not been decided on or before that day. We assessed 355 the longitudinal patterns of missingness (Supplementary Fig. S2) and multiply imputed 356 (m=100) these variables with the multivariate, time-series algorithm from the Amelia II 357 package<sup>32</sup> (v1.7.6) in R over the first week of ICU stay. The algorithm exploits both 358 359 between-variable and within-variable correlation structures over time to stochastically impute missing time series values in independently trained runs. We validated the MAR 360 assumption by identifying characteristics significantly associated with longitudinal 361 362 variable missingness (Supplementary Table S1) and included auxiliary information associated with value missingness (e.g., reasons for stopping ICP monitoring) in the 363 imputation model. 364

365

#### 366 Statistical inference

367

We calculated 95% confidence intervals (CI) for  $\rho$ ,  $r_{rm}$ ,  $\beta_{LMER}$ , AUC, sensitivity, specificity, a, and IC values using bootstrapping with 1,000 resamples of unique patients. For each resample, one of the 100 missing value imputations was randomly chosen. Therefore, confidence intervals represented the uncertainty due to patient resampling and missing value imputation.

- 373
- 374 **Code**
- 375

All statistical analyses were performed in Python (v3.8.2) or R, and all visualisations were created in R. All scripts used in this study are publicly available on GitHub: <u>https://github.com/sbhattacharyay/CENTER-TBI\_TIL</u>.

379

#### 380 **Results**

381

## 382 Study population

383

Of the 4,509 patients available for analysis in the CENTER-TBI core study, 873 patients from 52 ICUs met the additional inclusion criteria of this work. Amongst them, 837

constituted the TIL-ICP<sub>EH</sub> sub-population and 259 constituted the TIL-ICP<sub>HR</sub> subpopulation (Fig. 1). Summary characteristics of the overall population as well as those of the TIL-ICP<sub>EH</sub> and TIL-ICP<sub>HR</sub> sub-populations are detailed in Table 2. Apart from two of the prognosis scores pertaining to the probability of returning to pre-injury life roles (i.e., Pr(GOSE>5) and Pr(GOSE>6)), none of the tested characteristics were significantly different between patients in the TIL-ICP<sub>HR</sub> sub-population and those outside of it (Table 2).

393 The median ICU stay duration of our population was 14 days (IQR: 7.8-23 days), and 394 83% (n=726) stayed through at least seven calendar days. At each day of ICU stay, less 395 396 than 2.4% of the expected TIL scores were missing (Supplementary Fig. S2). Each TIL component item (Table 1) is represented by at least 17% (*n*=147, intracranial surgery) 397 and each sub-item is represented by at least 4.9% (n=43, high-dose mannitol) of the 398 population (Supplementary Table S2). The distributions of TIL<sub>max</sub>, TIL<sub>median</sub>, and TIL<sub>24</sub>, 399 juxtaposed against the scores of alternative scales (Table 1), are displayed in Fig. 2. The 400 distributions of TIL and PILOT were visually similar, and TIL<sup>(Basic)</sup>max had a strong ceiling 401 402 effect (i.e., 57% of the population had the maximum score). Whilst there was no significant difference in TIL<sub>24</sub> distribution over the first seven days, most patients had their highest 403 TIL<sub>24</sub> (i.e., TIL<sub>max</sub>) soon after ICU admission (median: day two, IQR: days one-three). The 404 405 Spearman's rank correlation coefficient ( $\rho$ ) between TIL<sub>max</sub> and TIL<sub>median</sub> was 0.80 (95%) CI: 0.77–0.82), and the median TIL<sub>median</sub>:TIL<sub>max</sub> ratio was 0.65 (IQR: 0.45–0.80). 406

407

## 408 Validation of TIL

409

The 95% CIs of  $\rho$  values, repeated measures correlation coefficients ( $r_{rm}$ ), and linear 410 mixed effect regression coefficients ( $\beta_{LMER}$ ) of TIL with other study measures are 411 412 visualised in Fig. 3. Both TILmax and TILmedian had mildly negative correlations (-0.26<pmean<-0.19) with baseline GCS, six-month GOSE, and functional outcome 413 414 prognoses (Fig. 3A–B). The within-individual association of TIL<sub>24</sub> with physician concerns of ICP was moderately positive (rm=0.35 [95% CI: 0.31-0.38]) and significantly higher 415 than that of TIL<sup>(Basic)</sup><sub>24</sub> (Fig. 3C). The association between ICP<sub>median</sub> and TIL<sub>median</sub> was 416 moderately positive (0.35< $\rho_{mean}$ <0.45) with both ICP<sub>EH</sub> and ICP<sub>HR</sub> values, and the 417 association between ICP<sub>max</sub> and TIL<sub>max</sub> was moderately positive ( $\rho$ =0.41 [95% CI: 0.33– 418 0.46]) with ICP<sub>EH</sub> values. The ICP<sub>max</sub> vs. TIL<sub>max</sub> correlation was not significant ( $\rho$ =0.01 419 420 [95% CI: -0.16–0.17]) with ICP<sub>HR</sub> values; however, without imputing missing ICP<sub>HR</sub> values, the  $\rho$  was 0.43 (95% CI: 0.35–0.50). This suggests that the longitudinal 421 422 missingness of ICP<sub>HR</sub> (Supplementary Fig. S2) for our sample size made the ICP<sub>max</sub> estimation significantly imprecise. Additionally, the within-individual association with ICP<sub>24</sub> 423 was either weak or not significant for any daily scale score according to  $r_{rm}$  (Fig. 3C) and 424  $\beta_{LMER}$  (Fig. 3D) values. On average, a single point increase in TIL<sub>24</sub> was associated with 425 a 0.22 (95% CI: 0.15-0.30) mmHg increase in daily mean ICPEH and a 0.19 (95% CI: -426 0.06–0.43) mmHg increase in daily mean ICP<sub>HR</sub>. These results mostly affirm the 427 convergent validity of TIL but highlight the broad intra-patient variability between ICP and 428 therapeutic intensity. From the distribution of ICP<sub>24</sub> values at each TIL<sub>24</sub> score (Fig. 4A), 429 we observed both considerable ICP<sub>24</sub> overlap across each TIL<sub>24</sub> score and an overall 430 positive relationship between  $TIL_{24}$  and  $ICP_{24}$ , particularly for  $TIL_{24} \ge 8$ . 431

432

The correlation between TIL and both prior scales (i.e., PILOT and TIL<sup>(1987)</sup>) was positively strong for maximum, median, and daily scores (Supplementary Fig. S3), establishing the criterion validity of TIL. According to 95% CIs, the association of TIL with prior scales was stronger than that of uwTIL or TIL<sup>(Basic)</sup> (Supplementary Fig. S3).

437

According to  $\rho$ ,  $r_{rm}$ , and  $\beta_{LMER}$  values (Fig. 3), the associations of TIL with CPP and of TIL with physician concerns of CPP were weaker than or not significantly different from the corresponding associations with ICP. Moreover, the trend of CPP<sub>24</sub> distributions over different TIL<sub>24</sub> scores is not as visually apparent as that of ICP<sub>24</sub> distributions over different TIL<sub>24</sub> scores (Fig. 4B). These results support the discriminant validity of TIL.

443

In our population, 157 patients (18% of 864 assessed) were reported to experience 444 refractory intracranial hypertension during ICU stay. TILmax correctly discriminated these 445 patients from the others 81% (95% CI: 78–84%) of the time (Fig. 5A), and TIL<sub>median</sub> did so 446 83% (95% CI: 80–86%) of the time (Fig. 5B). This performance of TIL was significantly 447 greater than or similar to that of all alternative scales (Fig. 5A–B). Furthermore, TIL<sub>median</sub> 448 had significantly greater discrimination performance than ICP<sub>max</sub> (Fig. 5C) and ICP<sub>median</sub> 449 (Fig. 5D), respectively. The sensitivity and specificity of refractory intracranial 450 hypertension detection at each threshold of TIL<sub>max</sub>, TIL<sub>median</sub>, TIL<sup>(Basic)</sup><sub>max</sub>, and 451 TIL<sup>(Basic)</sup><sub>median</sub> are listed in Supplementary Table S3 and visualised in Fig. 5C–D. The 452 thresholds which maximised the sum of sensitivity and specificity were TIL<sub>max</sub>≥14 453 (sensitivity: 68% [95% CI: 62–74%], specificity: 79% [95% CI: 77–81%]) and TIL<sub>median</sub>≥7.5 454 (sensitivity: 81% [95% CI: 77-87%], specificity: 72% [95% CI: 70-75%]) (Table 3). 455

456

## 457 **TIL component items**

458

Whilst there was wide variation in item combinations per TIL<sub>24</sub> score (i.e., sum of median 459 460 scores was often under diagonal line in Fig. 6A), the average order of therapeutic escalation was fairly consistent: position, sedation, CPP management, ventilatory 461 462 management, neuromuscular blockade, hyperosmolar therapy, temperature control, and then surgery for refractory ICP. Surgical control of ICP occurred in over 50% of reported 463 cases at each TIL<sub>24</sub> above 18 (Fig. 6A), but the threshold which maximised the sum of 464 sensitivity and specificity in detecting surgical ICP control was  $TIL_{24} \ge 9$  (Table 3, 465 466 performance at each threshold is listed in Supplementary Table S4). The inter-item  $r_{rm}$ values of TIL<sub>24</sub> (Supplementary Fig. S4) were mostly positive except for cerebrospinal 467 fluid (CSF) drainage, which did not correlate significantly with most other items, and 468 decompressive craniectomy, which did not correlate significantly with CSF, ventilatory, or 469 temperature control. Consistent with Fig. 6A, this result suggested that CSF drainage and 470 decompressive craniectomy were the most variably applied therapies across study ICUs. 471 472 The Cronbach's alpha ( $\alpha$ ) value of TIL<sub>24</sub> was, at best, 0.65 (95% CI: 0.62–0.68) and lower 473 (albeit, not significantly) than that of uwTIL<sub>24</sub> at each day of ICU stay (Supplementary Fig. S5). However, since TIL is a formative scale (i.e., the construct is multidimensional and 474 defined by the items), high inter-item correlation and  $\alpha$  values are not necessary for item 475 validation.<sup>17</sup> Amongst all TIL<sub>24</sub> items, sedation was most strongly correlated with adjusted 476 477 TIL<sub>24</sub> scores and physician concerns of ICP (Fig. 6B). From 10≤TIL<sub>24</sub>≤20, a plateau effect

of high-dose sedation combined with neuromuscular blockade was observed in most
cases (Fig. 6A). When accounting for all other TIL<sub>24</sub> sub-items, time since ICU admission,
as well as inter-patient variability, ventilation, mannitol administration, and hypertonic
saline administration were most strongly associated with ICP<sub>24</sub> and vasopressors were
most strongly associated with CPP<sub>24</sub> (Fig. 6C).

483

#### 484 **TIL**(Basic)

485

Based on the median TIL<sup>(Basic)</sup><sub>24</sub> score at each TIL<sub>24</sub> score (Fig. 7A), we derived the ranges 486 for mapping TIL<sub>24</sub> onto TIL<sup>(Basic)</sup><sub>24</sub> in Table 3. There is, however, considerable overlap of 487 TIL<sub>24</sub> scores across TIL<sup>(Basic)</sup><sub>24</sub> scores (Fig. 7B), particularly in the range of  $6 \le TIL_{24} \le 10$ . 488 TIL<sup>(Basic)</sup><sub>24</sub>=3 was not the most represented score at any TIL<sub>24</sub> score (Fig. 7A). TIL<sup>(Basic)</sup><sub>24</sub> 489 490 covered up to 33% (95% CI: 31–34%) of the information (i.e., entropy) in TIL<sub>24</sub>, and TIL<sup>(Basic)</sup><sub>median</sub> covered up to 28% (95% CI: 27–30%) of the information in TIL<sub>median</sub> (Fig. 491 7C). TIL<sup>(Basic)</sup>max only covered 17% (95% CI: 16–18%) of the information in TILmax (Fig. 492 493 7C). 494

## 495 **Discussion**

496

In this work, we performed a large-scale (*n*=873), multicentre (52 ICUs, 19 countries), and prospective validation study of TIL and TIL<sup>(Basic)</sup> against alternative scales. Our results support the validity of TIL as a metric for scoring ICP-directed therapeutic intensity. The dataset we used, as part of the CENTER-TBI study, not only reflects the modern variation in ICP-directed therapeutic intensity (Fig. 2 and Fig. 6A) but also illustrates the practical feasibility of daily TIL assessment: out of 885 eligible patients, 873 (99%) had daily TIL scores (Fig. 1) with less than 2.4% daily missingness (Supplementary Fig. S2).

504

We scrutinised and validated the use of TIL as a metric for scoring ICP-directed 505 therapeutic intensity and for marking pathophysiological severity. The statistical construct 506 and criterion validity measures of TIL were significantly greater or similar to those of 507 508 alternative scales (Fig. 3 and Fig. 5), and TIL integrated the widest range of modern ICP treatments (Table 1). Summarised TIL scores outperformed summarised ICP values in 509 detecting refractory intracranial hypertension. Our analysis yielded empirical ranges for 510 interpreting TIL in terms of refractory intracranial hypertension, surgical intervention, and 511 the condensed, TIL<sup>(Basic)</sup> scores (Table 3). On a component level (Fig. 6A), TIL<sub>24</sub> reflected 512 a pattern of treatment intensity escalation consistent with clinical algorithms<sup>2,3,5</sup> as well as 513 a wide variation in treatment combinations, particularly in the use of CSF drainage and 514 515 decompressive craniectomy. This finding is consistent with a previous CENTER-TBI study – which revealed inter-centre variation in TIL treatment selection and time to 516 administration<sup>12</sup> – and encourages an investigation of differences in TIL and long-term 517 outcome between centres with known differences in ICP management strategies. In 518 summary, our results support the use of TIL as an intermediate outcome for treatment 519 effect, as done in previous studies.<sup>33–35</sup> 520 521

Page 13 of 27

522 Due to a strong ceiling effect (Fig. 2A and Fig. 5A), TIL<sup>(Basic)</sup> should not be used instead 523 of TIL for rating maximum treatment intensity. TIL<sup>(Basic)</sup><sub>24</sub> and TIL<sub>median</sub> covered up to 33% 524 of the information in TIL<sub>24</sub> (Fig. 7C), but the TIL<sup>(Basic)</sup><sub>24</sub> associations with physician 525 concerns of ICP were significantly worse than those of TIL<sub>24</sub> (Fig. 3C). TIL should always 526 be preferred to TIL<sup>(Basic)</sup>, but we believe daily or median TIL<sup>(Basic)</sup> can be a suitable 527 alternative when daily or median TIL assessment is infeasible.

528

Moreover, we evaluated TIL with both end-hour (ICP<sub>EH</sub>) and high-resolution (ICP<sub>HR</sub>) ICP 529 values. ICP<sub>HR</sub>, if available, should be considered the gold standard in terms of precision 530 and granularity of the information provided, and neuromonitoring-related results from the 531 ICP<sub>HR</sub> population should generally take precedence.<sup>14</sup> However, 67% of expected ICP<sub>HR</sub> 532 values were missing on day one of ICU stay (Supplementary Fig. S2), likely due to the 533 time required to arrange high-resolution data collection. Consequently, estimates of high-534 resolution ICP<sub>max</sub> were significantly affected by missing value imputation and became 535 imprecise at our sample size (Fig. 3A). In these cases, results from the ICP<sub>EH</sub> population 536 served as a valuable reference on a substantially larger sample size (Table 2) since ICPEH 537 and CPP<sub>EH</sub> have been shown to be fair end-hour representations of ICP<sub>HR</sub> and CPP<sub>HR</sub>. 538 respectively, in CENTER-TBI.<sup>14</sup> The considerable overlap of ICP<sub>24</sub> values across TIL<sub>24</sub> 539 scores (both at low and high levels of ICP, Fig. 4A) and the insignificant-to-weak, within-540 individual association between ICP<sub>24</sub> and TIL<sub>24</sub> (Fig. 3C–D) highlight the need to account 541 for therapeutic intensity when interpreting ICP. Additionally, the higher median ICP<sub>24</sub> 542 values for TIL<sub>24</sub>≥8 (Fig. 4A) may suggest that clinicians accept a slightly higher ICP when 543 balancing the risks of elevating therapeutic intensity against those of intracranial 544 545 hypertension.

546

We see three main opportunities to improve TIL. First, the item scores of TIL and its 547 predecessors (i.e., PILOT and TIL<sup>(1987)</sup>) were not derived empirically. Data-driven 548 techniques, such as confirmatory factor analysis,<sup>28</sup> can be used to derive scoring 549 configurations which optimise a defined objective (e.g., maximal separation of patients). 550 However, data-driven scores do not necessarily reflect the intended construct (i.e., 551 treatment risk and complexity),<sup>36</sup> and, in general, item scoring does not have an 552 appreciable impact on overall scale performance.<sup>28</sup> Second, the items of TIL must evolve 553 as therapeutic approaches to ICP management evolve. TIL discriminated refractory 554 intracranial hypertension status significantly better than TIL<sup>(1987)</sup> (Fig. 5A–B) because TIL 555 updated TIL<sup>(1987)</sup> with six additional items (Table 1). We recommend updating and re-556 evaluating TIL each time ICP-treatment modalities or their perceived risks change. 557 Finally, the development of TIL was largely informed by the perspective of ICU practices 558 in high-income countries.<sup>8</sup> Likewise, this assessment was performed in a cohort of 559 patients across Europe and Israel. Especially given the disproportionately higher burden 560 of TBI in low- and middle-income countries,<sup>37</sup> it is imperative to test and, if necessary, 561 adapt TIL to a more inclusive, global population of TBI. 562

563

564 By design, TIL does not encompass all facets of modern intensive care for TBI patients. 565 Brain tissue oxygen tension (PbtO<sub>2</sub>),<sup>38</sup> cerebral microdialysis,<sup>39</sup> and brain temperature<sup>40</sup> 566 have emerged as multimodal, neuromonitoring targets which may affect ICU 567 management in addition to ICP or CPP. Therefore, TIL should be interpreted not as

568 general treatment intensity but rather as the intensity of ICP-directed therapy specifically. 569 We encourage the development and validation of clinical scales assessing the intensity 570 of TBI treatments directed at other physiological targets. Since treatments for other 571 targets often overlap with those for ICP or CPP (e.g., vasopressors target both PbtO<sub>2</sub> and 572 CPP),<sup>2</sup> we also promote a consolidation of all TBI treatments in an overall therapeutic 573 intensity scale which considers the effect of each treatment on multiple physiological 574 targets.

575

We recognise several limitations of our analysis. Whilst numerous investigators assessed 576 TIL across the study ICUs, each TIL score was only assessed once. Therefore, we could 577 not evaluate the interrater reliability of TIL. Similarly, data needed to calculate the full TIL 578 score was only recorded once a day, so we could not determine if a daily assessment 579 frequency was sufficient. Since the prior TIL validation study reported a high interrater 580 reliability and recommended a daily assessment frequency,<sup>9</sup> we assumed both to be true. 581 The results from the Randomised Evaluation of Surgery with Craniectomy for 582 Uncontrollable Elevation of Intracranial Pressure (RESCUEicp) trial<sup>41</sup> – published amidst 583 584 CENTER-TBI patient recruitment in 2016 – have likely changed the global frequency and perceived intensity of decompressive craniectomy for TBI. Therefore, we recognise the 585 potentially confounding effect of the trial results on treatment decision making for some 586 587 patients in the CENTER-TBI population and encourage a potential reappraisal of the therapeutic intensity of decompressive craniectomy through expert discussion and 588 statistical validation. The physician impressions (i.e., physician concerns of ICP and CPP 589 and refractory intracranial hypertension status) were subjective, and we did not have 590 enough information to account for interrater variability. Therefore, these scores and labels 591 should be considered unrefined. Finally, because of limited dosage data for numerical 592 593 treatments (i.e., CSF drainage, ventilation, hyperosmolar therapy, and temperature control), we did not test alternative sub-item categorisations. 594 595

## 596 Conclusion

597

TIL is a valid, generalisable measurement of ICP management amongst neuro-monitored 598 599 TBI patients in the ICU. On all validation metrics, TIL performs at least as well as its alternatives and considers the widest range of modern treatment strategies. TIL's 600 component scores over increasing TIL reflect a clinically credible order of treatment 601 602 escalation, from head positioning to ICP-directed surgery. TIL<sup>(Basic)</sup> is not suitable for evaluating maximum treatment intensity, but daily TIL<sup>(Basic)</sup> and median TIL<sup>(Basic)</sup> can cover 603 up to a third of the information in TIL. In the setting of clinical ICP management, TIL is a 604 more sensitive marker of pathophysiological severity than ICP and can be considered an 605 606 intermediate outcome after TBI.

607

# **Transparency, Rigor and Reproducibility Summary**

The CENTER-TBI study was pre-registered at clinicaltrials.gov (NCT02210221,
 <u>https://clinicaltrials.gov/ct2/show/NCT02210221</u>). The analysis plan was registered after
 beginning data collection but before data analysis at <u>https://www.center-</u>

tbi.eu/data/approved-proposals (#491), and the lead author with primary responsibility for 613 the analysis certifies that the analysis plan was pre-specified. A sample size of 903 614 patients was planned based on availability of critically ill, ICP-monitored, adult TBI 615 616 patients recruited for CENTER-TBI. Actual sample size was 873, as 18 patients had a documented decision to WLST on the first day of ICU stay and 12 additional patients did 617 not have daily TIL scores assessed. A patient inclusion diagram is provided (Fig. 1). TIL 618 scoring and clinical data entry was performed by investigators who were aware of relevant 619 characteristics of the participants. Participants were recruited between 19 December 620 2014 and 17 December 2017, and data (including follow-up results) were collected until 621 31 March 2021. High-resolution waveforms were stored directly from bedside monitoring 622 software, as described in the Methods and Materials. Variability amongst different TIL 623 assessors is not expected to be significant based on the established high interrater 624 reliability of TIL.<sup>9</sup> All equipment and software used to perform imaging and preprocessing 625 are widely available from commercial sources or open source repositories. The clinimetric 626 validation procedure and the primary clinical metric (TIL) are established standards in the 627 field, based on previously published results<sup>9,28</sup> and this study. The assumption of 628 629 bootstrapping-derived confidence intervals is that the sample is representative of the population. This study is, itself, an external validation, and internal replication by the study 630 group was performed. Individual participant data are available online, conditional to 631 632 approved online study proposal, with no end date at https://www.center-tbi.eu/data. Signed confirmation of a data access agreement is required, and all access must comply 633 with regulatory restrictions imposed on the original study. All analytic code used to 634 perform the statistical analyses publicly available online 635 are at: https://github.com/sbhattacharyay/CENTER-TBI\_TIL. This paper will be published under 636 a Creative Commons Open Access license, and upon publication, will be freely available 637 638 at https://www.liebertpub.com/loi/neu.

639

## 640 Acknowledgments

641

We are grateful to the patients and families of our study for making our efforts to improve
 TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University)
 for offering comments on the manuscript.

# 646 Author contributions

647

S.B. co-conceptualised the aims, developed the methodology and design, curated, 648 analysed, and visualised the data, acquired funding, and wrote the manuscript. E.B. 649 650 curated and analysed data, acquired funding, and reviewed the manuscript. P.Z. and L.W. curated data, aided in the development of methodology, and reviewed the manuscript. 651 EWS and DWN curated data, acquired funding, advised statistical analysis, and reviewed 652 653 the manuscript. A.I.R.M. and D.K.M. curated data, acquired funding, co-conceptualised 654 the aims, co-developed the methodology, and reviewed the manuscript. A.E. served as principal investigator, curated data, conceptualised the aims, co-developed the 655 656 methodology, and reviewed the manuscript. All authors read and approved the final manuscript. 657

#### 658 659 **Conflicts of interest**

661 All authors declare no financial or non-financial competing interests.

## 663 Funding statement

664

660

662

This research was supported by the National Institute for Health Research (NIHR) Brain 665 Injury MedTech Co-operative. CENTER-TBI was supported by the European Union 7th 666 Framework programme (EC grant 602150). Additional funding was obtained from the 667 Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences 668 Corporation (USA), and from NeuroTrauma Sciences (USA), CENTER-TBI also 669 acknowledges interactions and support from the International Initiative for TBI Research 670 (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded 671 by the Medical Research Council (MR N013433-1) and by a Gates Cambridge 672 673 Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 674

675

# 676 The CENTER-TBI investigators and participants

677

680

The co-lead investigators of CENTER-TBI are designated with an asterisk (\*), and their contact email addresses are listed below.

Cecilia Åkerlund<sup>1</sup>, Krisztina Amrein<sup>2</sup>, Nada Andelic<sup>3</sup>, Lasse Andreassen<sup>4</sup>, Audny Anke<sup>5</sup>, 681 Anna Antoni<sup>6</sup>, Gérard Audibert<sup>7</sup>, Philippe Azouvi<sup>8</sup>, Maria Luisa Azzolini<sup>9</sup>, Ronald Bartels<sup>10</sup>, 682 Pál Barzó<sup>11</sup>, Romuald Beauvais<sup>12</sup>, Ronny Beer<sup>13</sup>, Bo-Michael Bellander<sup>14</sup>, Antonio Belli<sup>15</sup>, 683 Habib Benali<sup>16</sup>, Maurizio Berardino<sup>17</sup>, Luigi Beretta<sup>9</sup>, Morten Blaabjerg<sup>18</sup>, Peter Bragge<sup>19</sup>, 684 Alexandra Brazinova<sup>20</sup>, Vibeke Brinck<sup>21</sup>, Joanne Brooker<sup>22</sup>, Camilla Brorsson<sup>23</sup>, Andras 685 Buki<sup>24</sup>, Monika Bullinger<sup>25</sup>, Manuel Cabeleira<sup>26</sup>, Alessio Caccioppola<sup>27</sup>, Emiliana 686 Calappi<sup>27</sup>, Maria Rosa Calvi<sup>9</sup>, Peter Cameron<sup>28</sup>, Guillermo Carbayo Lozano<sup>29</sup>, Marco 687 Carbonara<sup>27</sup>, Simona Cavallo<sup>17</sup>, Giorgio Chevallard<sup>30</sup>, Arturo Chieregato<sup>30</sup>, Giuseppe 688 Citerio<sup>31,32</sup>, Hans Clusmann<sup>33</sup>, Mark Coburn<sup>34</sup>, Jonathan Coles<sup>35</sup>, Jamie D. Cooper<sup>36</sup>, 689 Marta Correia<sup>37</sup>, Amra Čović<sup>38</sup>, Nicola Curry<sup>39</sup>, Endre Czeiter<sup>24</sup>, Marek Czosnyka<sup>26</sup>, Claire 690 Dahyot-Fizelier<sup>40</sup>, Paul Dark<sup>41</sup>, Helen Dawes<sup>42</sup>, Véronique De Keyser<sup>43</sup>, Vincent Degos<sup>16</sup>, 691 Francesco Della Corte<sup>44</sup>, Hugo den Boogert<sup>10</sup>, Bart Depreitere<sup>45</sup>, Đula Đilvesi<sup>46</sup>, Abhishek 692 Dixit<sup>47</sup>, Emma Donoghue<sup>22</sup>, Jens Dreier<sup>48</sup>, Guy-Loup Dulière<sup>49</sup>, Ari Ercole<sup>47</sup>, Patrick 693 Esser<sup>42</sup>, Erzsébet Ezer<sup>50</sup>, Martin Fabricius<sup>51</sup>, Valery L. Feigin<sup>52</sup>, Kelly Foks<sup>53</sup>, Shirin 694 Frisvold<sup>54</sup>, Alex Furmanov<sup>55</sup>, Pablo Gagliardo<sup>56</sup>, Damien Galanaud<sup>16</sup>, Dashiell Gantner<sup>28</sup>, 695 Guoyi Gao<sup>57</sup>, Pradeep George<sup>58</sup>, Alexandre Ghuysen<sup>59</sup>, Lelde Giga<sup>60</sup>, Ben Glocker<sup>61</sup>, 696 Jagoš Golubovic<sup>46</sup>, Pedro A. Gomez<sup>62</sup>, Johannes Gratz<sup>63</sup>, Benjamin Gravesteijn<sup>64</sup>, Francesca Grossi<sup>44</sup>, Russell L. Gruen<sup>65</sup>, Deepak Gupta<sup>66</sup>, Juanita A. Haagsma<sup>64</sup>, Iain 697 698 Haitsma<sup>67</sup>, Raimund Helbok<sup>13</sup>, Eirik Helseth<sup>68</sup>, Lindsay Horton<sup>69</sup>, Jilske Huijben<sup>64</sup>, Peter 699 J. Hutchinson<sup>70</sup>, Bram Jacobs<sup>71</sup>, Stefan Jankowski<sup>72</sup>, Mike Jarrett<sup>21</sup>, Ji-yao Jiang<sup>58</sup>, Faye 700 Johnson<sup>73</sup>, Kelly Jones<sup>52</sup>, Mladen Karan<sup>46</sup>, Angelos G. Kolias<sup>70</sup>, Erwin Kompanje<sup>74</sup>, Daniel 701 Kondziella<sup>51</sup>, Evgenios Kornaropoulos<sup>47</sup>, Lars-Owe Koskinen<sup>75</sup>, Noémi Kovács<sup>76</sup>, Ana 702

Kowark<sup>77</sup>, Alfonso Lagares<sup>62</sup>, Linda Lanyon<sup>58</sup>, Steven Laureys<sup>78</sup>, Fiona Lecky<sup>79,80</sup>, Didier 703 Ledoux<sup>78</sup>, Rolf Lefering<sup>81</sup>, Valerie Legrand<sup>82</sup>, Aurelie Lejeune<sup>83</sup>, Leon Levi<sup>84</sup>, Roger Lightfoot<sup>85</sup>, Hester Lingsma<sup>64</sup>, Andrew I.R. Maas<sup>43,86,\*</sup>, Ana M. Castaño-León<sup>62</sup>, Marc 704 705 Maegele<sup>87</sup>, Marek Majdan<sup>20</sup>, Alex Manara<sup>88</sup>, Geoffrey Manley<sup>89</sup>, Costanza Martino<sup>90</sup>, 706 Hugues Maréchal<sup>49</sup>, Julia Mattern<sup>91</sup>, Catherine McMahon<sup>92</sup>, Béla Melegh<sup>93</sup>, David Menon<sup>47,\*</sup>, Tomas Menovsky<sup>43,86</sup>, Ana Mikolic<sup>64</sup>, Benoit Misset<sup>78</sup>, Visakh 707 Menon<sup>47,\*</sup>, 708 Muraleedharan<sup>58</sup>, Lynnette Murray<sup>28</sup>, Ancuta Negru<sup>94</sup>, David Nelson<sup>1</sup>, Virginia 709 Newcombe<sup>47</sup>, Daan Nieboer<sup>64</sup>, József Nyirádi<sup>2</sup>, Otesile Olubukola<sup>79</sup>, Matej Oresic<sup>95</sup>, 710 Fabrizio Ortolano<sup>27</sup>, Aarno Palotie<sup>96,97,98</sup>, Paul M. Parizel<sup>99</sup>, Jean-François Payen<sup>100</sup>, 711 Natascha Perera<sup>12</sup>, Vincent Perlbarg<sup>16</sup>, Paolo Persona<sup>101</sup>, Wilco Peul<sup>102</sup>, Anna Piippo-712 Karjalainen<sup>103</sup>, Matti Pirinen<sup>96</sup>, Dana Pisica<sup>64</sup>, Horia Ples<sup>94</sup>, Suzanne Polinder<sup>64</sup>, Inigo 713 Pomposo<sup>29</sup>, Jussi P. Posti<sup>104</sup>, Louis Puybasset<sup>105</sup>, Andreea Radoi<sup>106</sup>, Arminas 714 Ragauskas<sup>107</sup>, Rahul Raj<sup>103</sup>, Malinka Rambadagalla<sup>108</sup>, Isabel Retel Helmrich<sup>64</sup>, Jonathan 715 Rhodes<sup>109</sup>, Sylvia Richardson<sup>110</sup>, Sophie Richter<sup>47</sup>, Samuli Ripatti<sup>96</sup>, Saulius Rocka<sup>107</sup>, Cecilie Roe<sup>111</sup>, Olav Roise<sup>112,113</sup>, Jonathan Rosand<sup>114</sup>, Jeffrey V. Rosenfeld<sup>115</sup>, Christina 716 717 Rosenlund<sup>116</sup>, Guy Rosenthal<sup>55</sup>, Rolf Rossaint<sup>77</sup>, Sandra Rossi<sup>101</sup>, Daniel Rueckert<sup>61</sup> 718 Martin Rusnák<sup>117</sup>, Juan Sahuquillo<sup>106</sup>, Oliver Sakowitz<sup>91,118</sup>, Renan Sanchez-Porras<sup>118</sup>, Janos Sandor<sup>119</sup>, Nadine Schäfer<sup>81</sup>, Silke Schmidt<sup>120</sup>, Herbert Schoechl<sup>121</sup>, Guus 719 720 Schoonman<sup>122</sup>, Rico Frederik Schou<sup>123</sup>, Elisabeth Schwendenwein<sup>6</sup>, Charlie Sewalt<sup>64</sup>, 721 Ranjit D. Singh<sup>102</sup>, Toril Skandsen<sup>124,125</sup>, Peter Smielewski<sup>26</sup>, Abayomi Sorinola<sup>126</sup>, 722 Emmanuel Stamatakis<sup>47</sup>, Simon Stanworth<sup>39</sup>, Robert Stevens<sup>127</sup>, William Stewart<sup>128</sup>, 723 Ewout W. Steyerberg<sup>64,129</sup>, Nino Stocchetti<sup>130</sup>, Nina Sundström<sup>131</sup>, Riikka Takala<sup>132</sup>, 724 Viktória Tamás<sup>126</sup>, Tomas Tamosuitis<sup>133</sup>, Mark Steven Taylor<sup>20</sup>, Aurore Thibaut<sup>78</sup>, Braden 725 Te Ao<sup>52</sup>, Olli Tenovuo<sup>104</sup>, Alice Theadom<sup>52</sup>, Matt Thomas<sup>88</sup>, Dick Tibboel<sup>134</sup>, Marjolein 726 Timmers<sup>74</sup>, Christos Tolias<sup>135</sup>, Tony Trapani<sup>28</sup>, Cristina Maria Tudora<sup>94</sup>, Andreas 727 Unterberg<sup>91</sup>, Peter Vajkoczy<sup>136</sup>, Shirley Vallance<sup>28</sup>, Egils Valeinis<sup>60</sup>, Zoltán Vámos<sup>50</sup>, 728 Mathieu van der Jagt<sup>137</sup>, Gregory Van der Steen<sup>43</sup>, Joukje van der Naalt<sup>71</sup>, Jeroen T.J.M. 729 van Dijck<sup>102</sup>, Inge A. M. van Erp<sup>102</sup>, Thomas A. van Essen<sup>102</sup>, Wim Van Hecke<sup>138</sup>, Caroline 730 van Heugten<sup>139</sup>, Ernest van Veen<sup>64</sup>, Thijs Vande Vyvere<sup>140</sup>, Roel P. J. van Wijk<sup>102</sup>, Alessia 731 Vargiolu<sup>32</sup>, Emmanuel Vega<sup>83</sup>, Kimberley Velt<sup>64</sup>, Jan Verheyden<sup>138</sup>, Paul M. Vespa<sup>141</sup>, 732 Anne Vik<sup>124,142</sup>, Rimantas Vilcinis<sup>133</sup>, Victor Volovici<sup>67</sup>, Nicole von Steinbüchel<sup>38</sup>, Daphne 733 Voormolen<sup>64</sup>, Petar Vulekovic<sup>46</sup>, Kevin K.W. Wang<sup>143</sup>, Daniel Whitehouse<sup>47</sup>, Eveline 734 Wiegers<sup>64</sup>, Guy Williams<sup>47</sup>, Lindsay Wilson<sup>69</sup>, Stefan Winzeck<sup>47</sup>, Stefan Wolf<sup>144</sup>, Zhihui 735 Yang<sup>114</sup>, Peter Ylén<sup>145</sup>, Alexander Younsi<sup>91</sup>, Frederick A. Zeiler<sup>47,146</sup>, Veronika 736 Zelinkova<sup>20</sup>, Agate Ziverte<sup>60</sup>, Tommaso Zoerle<sup>27</sup> 737

- 738
- <sup>1</sup>Department of Physiology and Pharmacology, Section of Perioperative Medicine and
   Intensive Care, Karolinska Institutet, Stockholm, Sweden
- <sup>2</sup>János Szentágothai Research Centre, University of Pécs, Pécs, Hungary
- <sup>3</sup>Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation,
   Oslo University Hospital and University of Oslo, Oslo, Norway
- <sup>4</sup>Department of Neurosurgery, University Hospital Northern Norway, Tromso, Norway
- <sup>5</sup>Department of Physical Medicine and Rehabilitation, University Hospital Northern
   Norway, Tromso, Norway
- <sup>6</sup>Trauma Surgery, Medical University Vienna, Vienna, Austria

- <sup>7</sup>Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy, 748 749 France
- <sup>8</sup>Raymond Poincare hospital, Assistance Publique Hopitaux de Paris, Paris, France 750
- 751 <sup>9</sup>Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan, Italy 752
- 753 <sup>10</sup>Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands 754
- <sup>11</sup>Department of Neurosurgery, University of Szeged, Szeged, Hungary 755
- <sup>12</sup>International Projects Management, ARTTIC, Munchen, Germany 756
- <sup>13</sup>Department of Neurology, Neurological Intensive Care Unit, Medical University of 757 758 Innsbruck, Innsbruck, Austria
- <sup>14</sup>Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska 759 University Hospital, Stockholm, Sweden 760
- <sup>15</sup>NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK 761
- <sup>16</sup>Anesthesie-Réanimation, Assistance Publique Hopitaux de Paris, Paris, France 762
- <sup>17</sup>Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino -763 764 Orthopedic and Trauma Center, Torino, Italy
- <sup>18</sup>Department of Neurology, Odense University Hospital, Odense, Denmark 765
- <sup>19</sup>BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria, 766 767 Australia
- <sup>20</sup>Department of Public Health, Faculty of Health Sciences and Social Work, Trnava 768 University, Trnava, Slovakia 769
- 770 <sup>21</sup>Quesgen Systems Inc., Burlingame, California, USA
- <sup>22</sup>Australian & New Zealand Intensive Care Research Centre, Department of 771 Epidemiology and Preventive Medicine, School of Public Health and Preventive 772 773 Medicine, Monash University, Melbourne, Australia
- <sup>23</sup>Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden 774
- <sup>24</sup>Department of Neurosurgery, Medical School, University of Pécs, Hungary and 775 Neurotrauma Research Group, János Szentágothai Research Centre, University of 776 777 Pécs, Hungary
- <sup>25</sup>Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf, 778 Hamburg, Germany 779
- <sup>26</sup>Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University 780 of Cambridge, Addenbrooke's Hospital, Cambridge, UK 781
- <sup>27</sup>Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy 782
- <sup>28</sup>ANZIC Research Centre, Monash University, Department of Epidemiology and 783 Preventive Medicine, Melbourne, Victoria, Australia 784
- <sup>29</sup>Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain 785
- 786 <sup>30</sup>NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- <sup>31</sup>School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy 787
- <sup>32</sup>NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo 788 789 dei Tintori, Monza, Italy
- <sup>33</sup>Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen, 790 791 Germanv
- 792 <sup>34</sup>Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn,
- Bonn, Germany 793

- <sup>35</sup>Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS
- 795 Foundation Trust, Cambridge, UK
- <sup>36</sup>School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne,
   Victoria, Australia
- <sup>37</sup>Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK
- <sup>38</sup>Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen,
   Göttingen, Germany
- <sup>39</sup>Oxford University Hospitals NHS Trust, Oxford, UK
- <sup>40</sup>Intensive Care Unit, CHU Poitiers, Potiers, France
- <sup>41</sup>University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate,
   Salford Royal Hospital NHS Foundation Trust, Salford, UK
- <sup>42</sup>Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
   University, Oxford, UK
- <sup>43</sup>Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium
- <sup>44</sup>Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara,
   Italy
- <sup>45</sup>Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- <sup>46</sup>Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
   University of Novi Sad, Novi Sad, Serbia
- <sup>47</sup>Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge,
   UK
- <sup>48</sup>Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin, corporate
   member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute
   of Health, Berlin, Germany
- <sup>49</sup>Intensive Care Unit, CHR Citadelle, Liège, Belgium
- <sup>50</sup>Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs,
   Hungary
- <sup>51</sup>Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region
   Hovedstaden Rigshospitalet, Copenhagen, Denmark
- <sup>52</sup>National Institute for Stroke and Applied Neurosciences, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand
- <sup>53</sup>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands
- <sup>54</sup>Department of Anesthesiology and Intensive care, University Hospital Northern Norway,
   Tromso, Norway
- <sup>55</sup>Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem,
   Israel
- <sup>56</sup>Fundación Instituto Valenciano de Neurorrehabilitación (FIVAN), Valencia, Spain
- <sup>57</sup>Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong
   University/school of medicine, Shanghai, China
- <sup>58</sup>Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,
   Stockholm, Sweden
- <sup>59</sup>Emergency Department, CHU, Liège, Belgium
- <sup>60</sup>Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
- <sup>61</sup>Department of Computing, Imperial College London, London, UK
- <sup>62</sup>Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain

- <sup>63</sup>Department of Anesthesia, Critical Care and Pain Medicine, Medical University of
   Vienna, Austria
- <sup>64</sup>Department of Public Health, Erasmus Medical Center-University Medical Center,
   Rotterdam, The Netherlands
- <sup>65</sup>College of Health and Medicine, Australian National University, Canberra, Australia
- <sup>66</sup>Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All
   India Institute of Medical Sciences, New Delhi-110029, India
- <sup>67</sup>Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- <sup>68</sup>Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- <sup>69</sup>Division of Psychology, University of Stirling, Stirling, UK
- <sup>70</sup>Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
   Hospital & University of Cambridge, Cambridge, UK
- <sup>71</sup>Department of Neurology, University of Groningen, University Medical Center
   Groningen, Groningen, Netherlands
- <sup>72</sup>Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,
   UK
- <sup>73</sup>Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford,
   UK
- <sup>74</sup>Department of Intensive Care and Department of Ethics and Philosophy of Medicine,
   Erasmus Medical Center, Rotterdam, The Netherlands
- <sup>75</sup>Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- <sup>76</sup>Hungarian Brain Research Program Grant No. KTIA\_13\_NAP-A-II/8, University of
   Pécs, Pécs, Hungary
- <sup>77</sup>Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- <sup>78</sup>Cyclotron Research Center, University of Liège, Liège, Belgium
- <sup>79</sup>Centre for Urgent and Emergency Care Research (CURE), Health Services Research
   Section, School of Health and Related Research (ScHARR), University of Sheffield,
   Sheffield, UK
- <sup>80</sup>Emergency Department, Salford Royal Hospital, Salford UK
- <sup>81</sup>Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,
   Cologne, Germany
- <sup>82</sup>VP Global Project Management CNS, ICON, Paris, France
- <sup>83</sup>Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- <sup>84</sup>Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- <sup>85</sup>Department of Anesthesiology & Intensive Care, University Hospitals Southhampton
   NHS Trust, Southhampton, UK
- <sup>86</sup>Department of Translational Neuroscience, Faculty of Medicine and Health Science,
   <sup>876</sup> University of Antwerp, Antwerp, Belgium
- <sup>87</sup>Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic
   <sup>87</sup>Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- <sup>879</sup><sup>88</sup>Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- <sup>89</sup>Department of Neurological Surgery, University of California, San Francisco, California,
   USA
- <sup>90</sup>Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- <sup>91</sup>Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- <sup>92</sup>Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK

- <sup>93</sup>Department of Medical Genetics, University of Pécs, Pécs, Hungary
- <sup>94</sup>Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
   Romania
- <sup>95</sup>School of Medical Sciences, Örebro University, Örebro, Sweden
- <sup>96</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- <sup>97</sup>Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric &
   Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of
- 892 Neurology, Massachusetts General Hospital, Boston, MA, USA
- <sup>98</sup>Program in Medical and Population Genetics; The Stanley Center for Psychiatric
   Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- <sup>99</sup>Department of Radiology, University of Antwerp, Edegem, Belgium
- <sup>100</sup>Department of Anesthesiology & Intensive Care, University Hospital of Grenoble,
   Grenoble, France
- <sup>101</sup>Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di
   Padova, Padova, Italy
- <sup>102</sup>Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and
   Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
- <sup>103</sup>Department of Neurosurgery, Helsinki University Central Hospital
- <sup>104</sup>Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury
   Centre, Turku University Hospital and University of Turku, Turku, Finland
- <sup>105</sup>Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,
   Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris,
   France
- <sup>106</sup>Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron
   Research Institute, Barcelona, Spain
- <sup>107</sup>Department of Neurosurgery, Kaunas University of technology and Vilnius University,
   Vilnius, Lithuania
- <sup>108</sup>Department of Neurosurgery, Rezekne Hospital, Latvia
- <sup>109</sup>Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University
   of Edinburg, Edinburgh, UK
- <sup>110</sup>Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- <sup>111</sup>Department of Physical Medicine and Rehabilitation, Oslo University
   Hospital/University of Oslo, Oslo, Norway
- <sup>112</sup>Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- <sup>113</sup>Institue of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- <sup>114</sup>Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts
   General Hospital, Boston MA, USA
- <sup>115</sup>National Trauma Research Institute, The Alfred Hospital, Monash University,
   Melbourne, Victoria, Australia
- <sup>116</sup>Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- <sup>117</sup>International Neurotrauma Research Organisation, Vienna, Austria
- <sup>118</sup>Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- <sup>119</sup>Division of Biostatistics and Epidemiology, Department of Preventive Medicine,
   University of Debrecen, Debrecen, Hungary
- <sup>120</sup>Department Health and Prevention, University Greifswald, Greifswald, Germany

- <sup>121</sup>Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg,
   Austria
- <sup>122</sup>Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- <sup>123</sup>Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital,
   Odense, Denmark
- <sup>124</sup>Department of Neuromedicine and Movement Science, Norwegian University of
   Science and Technology, NTNU, Trondheim, Norway
- <sup>125</sup>Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim
   <sup>125</sup>Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim
   <sup>938</sup>University Hospital, Trondheim, Norway
- <sup>126</sup>Department of Neurosurgery, University of Pécs, Pécs, Hungary
- <sup>127</sup>Division of Neuroscience Critical Care, John Hopkins University School of Medicine,
   Baltimore, USA
- <sup>128</sup>Department of Neuropathology, Queen Elizabeth University Hospital and University of
   Glasgow, Glasgow, UK
- <sup>129</sup>Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center,
   Leiden, The Netherlands
- <sup>130</sup>Department of Pathophysiology and Transplantation, Milan University, and
   Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,
   Milano, Italy
- <sup>131</sup>Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå,
   Sweden
- <sup>132</sup>Perioperative Services, Intensive Care Medicine and Pain Management, Turku
   <sup>132</sup>University Hospital and University of Turku, Turku, Finland
- <sup>133</sup>Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- <sup>134</sup>Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia
   <sup>55</sup> Children's Hospital, Rotterdam, The Netherlands
- <sup>135</sup>Department of Neurosurgery, Kings college London, London, UK
- <sup>136</sup>Neurologie, Neurochirurgie und Psychiatrie, Charité Universitätsmedizin Berlin,
   Berlin, Germany
- <sup>137</sup>Department of Intensive Care Adults, Erasmus MC– University Medical Center
   Rotterdam, Rotterdam, the Netherlands
- <sup>138</sup>icoMetrix NV, Leuven, Belgium
- <sup>139</sup>Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
   <sup>University</sup>, Oxford, UK
- <sup>140</sup>Radiology Department, Antwerp University Hospital, Edegem, Belgium
- <sup>965</sup> <sup>141</sup>Director of Neurocritical Care, University of California, Los Angeles, USA
- <sup>142</sup>Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital,
   Trondheim, Norway
- <sup>143</sup>Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
- <sup>144</sup>Department of Neurosurgery, Charité Universitätsmedizin Berlin, corporate member
- of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health,
- 971 Berlin, Germany
- <sup>145</sup>VTT Technical Research Centre, Tampere, Finland
- <sup>973</sup> <sup>146</sup>Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences,
- University of Manitoba, Winnipeg, MB, Canada
- 975

<sup>976</sup> \*Co-lead investigators: andrew.maas@uza.be (AIRM) and dkm13@cam.ac.uk (DM)

977

#### 978 **References**

979

- Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. N Engl J Med
   2014;370(22):2121–2130; doi: 10.1056/NEJMra1208708.
- 2. Meyfroidt G, Bouzat P, Casaer MP, et al. Management of moderate to severe traumatic brain injury: an update for the intensivist. Intensive Care Med
  2022;48(6):649–666; doi: 10.1007/s00134-022-06702-4.
- 3. Menon DK, Ercole A. Chapter 14 Critical care management of traumatic brain injury.
  Wijdicks EFM, Kramer AH. eds. Handb Clin Neurol 2017;140(Journal Article):239–
  274; doi: 10.1016/B978-0-444-63600-3.00014-3.
- 4. Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted
  management in the intensive care unit. Lancet Neurol 2017;16(6):452–464; doi:
  10.1016/S1474-4422(17)30118-7.
- 5. Hawryluk GWJ, Aguilera S, Buki A, et al. A management algorithm for patients with
  intracranial pressure monitoring: the Seattle International Severe Traumatic Brain
  Injury Consensus Conference (SIBICC). Intensive Care Med 2019;45(12):1783–
  1794; doi: 10.1007/s00134-019-05805-9.
- 6. Maset AL, Marmarou A, Ward JD, et al. Pressure-volume index in head injury. J
  Neurosurg 1987;67(6):832–840; doi: 10.3171/jns.1987.67.6.0832.

7. Shore PM, Hand LL, Roy L, et al. Reliability and validity of the Pediatric Intensity
Level of Therapy (PILOT) scale: A measure of the use of intracranial pressure–
directed therapies. Crit Care Med 2006;34(7):1981; doi:
10.1097/01.CCM.0000220765.22184.ED.


- 8. Maas AIR, Harrison-Felix CL, Menon D, et al. Standardizing Data Collection in Traumatic Brain Injury. J Neurotrauma 2011;28(2):177–187; doi: 10.1089/neu.2010.1617.
- 9. Zuercher P, Groen JL, Aries MJH, et al. Reliability and Validity of the Therapy
  Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to
  Assess Management of Intracranial Pressure in Traumatic Brain Injury. J
  Neurotrauma 2016;33(19):1768–1774; doi: 10.1089/neu.2015.4266.
- 1008 10. Robba C, Graziano F, Guglielmi A, et al. Treatments for intracranial hypertension
   in acute brain-injured patients: grading, timing, and association with outcome. Data
   from the SYNAPSE-ICU study. Intensive Care Med 2023;49(1):50–61; doi:
   10.1007/s00134-022-06937-1.

- Huijben JA, Wiegers EJA, Lingsma HF, et al. Changing care pathways and
  between-center practice variations in intensive care for traumatic brain injury across
  Europe: a CENTER-TBI analysis. Intensive Care Med 2020;46(5):995–1004; doi:
  10.1007/s00134-020-05965-z.
- Huijben JA, Dixit A, Stocchetti N, et al. Use and impact of high intensity
   treatments in patients with traumatic brain injury across Europe: a CENTER-TBI
   analysis. Crit Care 2021;25(1):78; doi: 10.1186/s13054-020-03370-y.
- 1019 13. Bhattacharyay S, Caruso PF, Åkerlund C, et al. Mining the contribution of
  intensive care clinical course to outcome after traumatic brain injury. Npj Digit Med
  2023;6(1):154; doi: 10.1038/s41746-023-00895-8.
- 1022 14. Zoerle T, Birg T, Carbonara M, et al. Accuracy of Manual Intracranial Pressure
   1023 Recording Compared to a Computerized High-Resolution System: A CENTER-TBI
   1024 Analysis. Neurocrit Care 2023; doi: 10.1007/s12028-023-01697-2.
- 1025 15. Maas AIR, Menon DK, Manley GT, et al. Traumatic brain injury: progress and
  1026 challenges in prevention, clinical care, and research. Lancet Neurol
  1027 2022;21(11):1004–1060; doi: 10.1016/S1474-4422(22)00309-X.
- 1028 16. Cnossen MC, Huijben JA, van der Jagt M, et al. Variation in monitoring and
   1029 treatment policies for intracranial hypertension in traumatic brain injury: a survey in 66
   1030 neurotrauma centers participating in the CENTER-TBI study. Crit Care
   1031 2017;21(1):233; doi: 10.1186/s13054-017-1816-9.
- 1032 17. Avila ML, Stinson J, Kiss A, et al. A critical review of scoring options for clinical
  1033 measurement tools. BMC Res Notes 2015;8(1):612; doi: 10.1186/s13104-015-15611034 6.
- Maas AIR, Menon DK, Steyerberg EW, et al. Collaborative European
   NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A
   Prospective Longitudinal Observational Study. Neurosurgery 2015;76(1):67–80; doi:
   10.1227/NEU.0000000000575.
- 1039
  19. Steyerberg EW, Wiegers E, Sewalt C, et al. Case-mix, care pathways, and
  1040
  1041 outcomes in patients with traumatic brain injury in CENTER-TBI: a European
  1041 prospective, multicentre, longitudinal, cohort study. Lancet Neurol 2019;18(10):923–
  1042 934; doi: 10.1016/S1474-4422(19)30232-7.
- 20. Doiron D, Marcon Y, Fortier I, et al. Software Application Profile: Opal and Mica:
  open-source software solutions for epidemiological data management, harmonization
  and dissemination. Int J Epidemiol 2017;46(5):1372–1378; doi: 10.1093/ije/dyx180.
- Zeiler FA, Ercole A, Cabeleira M, et al. Patient-specific ICP Epidemiologic
   Thresholds in Adult Traumatic Brain Injury: A CENTER-TBI Validation Study. J
   Neurosurg Anesthesiol 2021;33(1):28–38; doi: 10.1097/ANA.00000000000616.


- Marshall LF, Marshall SB, Klauber MR, et al. The diagnosis of head injury
   requires a classification based on computed axial tomography. J Neurotrauma 1992;9
   Suppl 1:S287-292.
- 1052 23. Teasdale G, Maas A, Lecky F, et al. The Glasgow Coma Scale at 40 years:
  1053 standing the test of time. The LancetNeurology 2014;13(8):844–854; doi:
  1054 10.1016/S1474-4422(14)70120-6.
- Ercole A, Dixit A, Nelson DW, et al. Imputation strategies for missing baseline
   neurological assessment covariates after traumatic brain injury: A CENTER-TBI
   study. PLoS ONE 2021;16(8):e0253425.
- McMillan T, Wilson L, Ponsford J, et al. The Glasgow Outcome Scale 40 years
  of application and refinement. Nat Rev Neurol 2016;12(8):477–485; doi:
  10.1038/nrneurol.2016.89.
- 1061 26. Kunzmann K, Wernisch L, Richardson S, et al. Imputation of Ordinal Outcomes:
  1062 A Comparison of Approaches in Traumatic Brain Injury. J Neurotrauma
  1063 2021;38(4):455–463; doi: 10.1089/neu.2019.6858.
- Bhattacharyay S, Milosevic I, Wilson L, et al. The leap to ordinal: Detailed
   functional prognosis after traumatic brain injury with a flexible modelling approach.
   PLoS ONE 2022;17(7):e0270973; doi: 10.1371/journal.pone.0270973.
- 1067 28. Boateng GO, Neilands TB, Frongillo EA, et al. Best Practices for Developing and
  1068 Validating Scales for Health, Social, and Behavioral Research: A Primer. Front Public
  1069 Health 2018;6:149; doi: 10.3389/fpubh.2018.00149.
- 107029. Bakdash JZ, Marusich LR. Repeated Measures Correlation. Front Psychol10712017;8:456; doi: 10.3389/fpsyg.2017.00456.
- 1072 30. van Buuren S, Groothuis-Oudshoorn CGM. mice: Multivariate Imputation by 1073 Chained Equations in R. J Stat Softw 2011;45(3):1–67; doi: 10.18637/jss.v045.i03.
- 1074 31. Gravesteijn BY, Sewalt CA, Venema E, et al. Missing Data in Prediction
  1075 Research: A Five-Step Approach for Multiple Imputation, Illustrated in the CENTER1076 TBI Study. J Neurotrauma 2021;38(13):1842–1857; doi: 10.1089/neu.2020.7218.
- 1077 32. Honaker J King, G, Blackwell,M. Amelia II: A Program for Missing Data. J Stat 1078 Softw 2011;45(7); doi: 10.18637/jss.v045.i07.
- 33. Beqiri E, Smielewski P, Robba C, et al. Feasibility of individualised severe traumatic brain injury management using an automated assessment of optimal cerebral perfusion pressure: the COGiTATE phase II study protocol. BMJ Open 2019;9(9):e030727; doi: 10.1136/bmjopen-2019-030727.
- 108334. Tas J, Beqiri E, van Kaam RC, et al. Targeting Autoregulation-Guided Cerebral1084Perfusion Pressure after Traumatic Brain Injury (COGiTATE): A Feasibility

- 1085 Randomized Controlled Clinical Trial. J Neurotrauma 2021;38(20):2790–2800; doi:
   10.1089/neu.2021.0197.
- 1087 35. van Erp IAM, van Essen TA, Fluiter K, et al. Safety and efficacy of C1-inhibitor in 1088 traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-1089 controlled, multi-center trial. Trials 2021;22(1):874; doi: 10.1186/s13063-021-05833-1090 1.
- Schreiber JB. Issues and recommendations for exploratory factor analysis and
   principal component analysis. Res Soc Adm Pharm 2021;17(5):1004–1011; doi:
   10.1016/j.sapharm.2020.07.027.
- 1094 37. Clark D, Joannides A, Adeleye AO, et al. Casemix, management, and mortality of 1095 patients receiving emergency neurosurgery for traumatic brain injury in the Global 1096 Neurotrauma Outcomes Study: a prospective observational cohort study. Lancet 1097 Neurol 2022;21(5):438–449; doi: 10.1016/S1474-4422(22)00037-0.
- 38. Okonkwo DO, Shutter LA, Moore C, et al. Brain Oxygen Optimization in Severe
  Traumatic Brain Injury Phase-II: A Phase II Randomized Trial\*. Crit Care Med
  2017;45(11):1907; doi: 10.1097/CCM.0000000002619.
- Hutchinson PJ, Jalloh I, Helmy A, et al. Consensus statement from the 2014
  International Microdialysis Forum. Intensive Care Med 2015;41(9):1517–1528; doi:
  10.1007/s00134-015-3930-y.
- 110440.Yokobori S, Yokota H. Targeted temperature management in traumatic brain1105injury. J Intensive Care 2016;4(1):28; doi: 10.1186/s40560-016-0137-4.
- 1106 41. Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of Decompressive
- 1107 Craniectomy for Traumatic Intracranial Hypertension. N Engl J Med
- 1108 2016;375(12):1119–1130; doi: 10.1056/NEJMoa1605215.

1109




**Fig. 1.** Flow diagram for patient enrolment and validation population assignment. Abbreviations: CENTER-TBI=Collaborative European NeuroTrauma Effectiveness Research in TBI, ICP=intracranial pressure, ICP<sub>EH</sub>=end-hour ICP, ICP<sub>HR</sub>=high-resolution ICP, ICU=intensive care unit, TBI=traumatic brain injury, TIL=Therapy Intensity Level scale,<sup>8,9</sup> WLST=withdrawal of life-sustaining therapies.





**Fig. 2. Distributions of TIL and alternative scales.** Abbreviations: ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,<sup>7</sup> TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(1987)</sup>=original Therapy Intensity Level scale published in 1987,<sup>6</sup> TIL<sup>(Basic)</sup>=condensed TIL scale,<sup>8</sup> uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index within the item. The numeric definition of each scale is listed in Table 1. (**A**) Distributions of maximum scores of TIL (i.e., TIL<sub>max</sub>) and alternative scales (i.e., uwTIL<sub>max</sub>, TIL<sup>(Basic)</sup><sub>max</sub>, PILOT<sub>max</sub>, and TIL<sup>(1987)</sup><sub>max</sub>) over the first week of ICU stay. (**B**) Distribution of median scores of TIL (i.e., TIL<sub>median</sub>) and alternative scales (i.e., uwTIL<sub>median</sub>, PILOT<sub>median</sub>, and TIL<sup>(1987)</sup><sub>median</sub>) over the first week of ICU stay. (**C**) Distributions of TIL (i.e., TIL<sub>24</sub>) and alternative scales (i.e., uwTIL<sub>24</sub>, TIL<sup>(Basic)</sup><sub>24</sub>, PILOT<sub>24</sub>, and TIL<sup>(1987)</sup><sub>24</sub>) over the first week of ICU stay.









**Fig. 3.** Associations of TIL and alternative scales with other clinical measures. Abbreviations: Day<sub>ICU</sub>=variable representing day (from 1 to 7) of ICU stay, EH=end-hour, CPP=cerebral perfusion pressure, GCS=Glasgow Coma Scale at ICU admission, GOSE=Glasgow Outcome Scale–Extended at six months post-injury, HR=high-resolution, ICP=intracranial pressure, ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,<sup>7</sup> Pr(GOSE>•)="probability of GOSE greater than • at six months post-injury" as previously calculated from the first 24 hours of admission,<sup>27</sup> TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(1987)</sup>=original Therapy Intensity Level scale published in 1987,<sup>6</sup> TIL<sup>(Basic)</sup>=condensed TIL scale,<sup>8</sup>

within the item. The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL<sub>24</sub>), maximum (e.g., TIL<sub>max</sub>), and median (e.g., TIL<sub>median</sub>) scores are described in the Methods. The bars represent 95% confidence intervals derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (**A**) Spearman's correlation coefficients ( $\rho$ ) between maximum scale scores over first week of ICU stay (i.e., TIL<sub>max</sub>, uwTIL<sub>max</sub>, TIL<sup>(Basic)</sup><sub>max</sub>, PILOT<sub>max</sub>, and TIL<sup>(1987)</sup><sub>max</sub>) and other clinical measures. (**B**) Spearman's correlation coefficients ( $\rho$ ) between median scale scores over first week of ICU stay (i.e., TIL<sub>median</sub>, uwTIL<sub>median</sub>, TIL<sup>(Basic)</sup><sub>median</sub>, PILOT<sub>median</sub>, and TIL<sup>(1987)</sup><sub>median</sub>) and other clinical measures. (**C**) Repeated measures correlation coefficients ( $r_{rm}$ , from -1 to 1) are interpreted as the strength and direction of association between two variables after accounting for inter-patient variation. (**D**) Linear mixed effects model coefficients ( $\beta_{LMER}$ ) are interpreted as the expected difference in dependent variable (e.g., EH ICP<sub>24</sub>) per unit increase of daily scale score (e.g., TIL<sub>24</sub>) after accounting for time since ICU admission (i.e., Day<sub>ICU</sub>) and inter-patient variation.





**Fig 4. Distributions of daily intracranial pressure and cerebral perfusion pressure means per daily TIL score.** Abbreviations: CPP=cerebral perfusion pressure, CPP<sub>24</sub>=mean CPP over calendar day, Day<sub>ICU</sub>=variable representing day (from 1 to 7) of ICU stay, EH=end-hour, HR=highresolution, ICP=intracranial pressure, ICP<sub>24</sub>=mean ICP over calendar day, TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sub>24</sub>=TIL score of calendar day, TIL-ICP<sub>EH</sub>=end-hour ICP sub-population, TIL-ICP<sub>HR</sub>=high-resolution ICP sub-population. The values in each panel are the linear mixed effects model coefficients ( $\beta_{LMER}$ ) of TIL<sub>24</sub> with 95% confidence intervals derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. The width of violin plots is scaled for each population, but the width of the points inside them demonstrates relative frequency across the populations. The violin plots do not encompass outliers based on 1.5 times the interquartile range. (**A**) Distributions of ICP<sub>24</sub> vs. TIL<sub>24</sub> for both sub-populations. (**B**) Distributions of CPP<sub>24</sub> vs. TIL<sub>24</sub> for both sub-populations.








Fig 5. Discrimination of refractory intracranial hypertension status by TIL and alternative scale summary scores. Abbreviations: AUC=area under the receiver operating characteristic curve, EH=end-hour, HR=high-resolution, ICP=intracranial pressure, ICP<sub>max</sub>=maximum calendar day mean of ICP over first week of ICU stay, ICP<sub>median</sub>=median calendar day mean of ICP over first week of ICU stay, ICU=intensive care unit, PILOT=Paediatric Intensity Level of Therapy scale,<sup>7</sup> TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(1987)</sup>=original Therapy Intensity Level scale published in 1987,<sup>6</sup> TIL<sup>(Basic)</sup>=condensed TIL scale,<sup>8</sup> uwTIL=unweighted TIL scale in which subitem scores are replaced by the ascending rank index within the item. The 95% confidence intervals of AUC were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (A) Distributions of maximum scores of TIL (i.e., TILmax) and alternative scales (i.e., uwTILmax, TIL<sup>(Basic)</sup>max, PILOTmax, and TIL<sup>(1987)</sup>max) stratified by refractory intracranial hypertension status. The horizontal black line segments represent the thresholds which maximised the sum of sensitivity and specificity for each scale. (B) Distributions of median scores of TIL (i.e., TIL<sub>median</sub>) and alternative scales (i.e., uwTIL<sub>median</sub>, TIL<sup>(Basic)</sup><sub>median</sub>, PILOT<sub>median</sub>, and TIL<sup>(1987)</sup>median) stratified by refractory intracranial hypertension status. The horizontal black line segments represent the thresholds which maximised the sum of sensitivity and specificity for each scale. (C) Receiver operating characteristic curve of refractory intracranial hypertension detection with TIL<sub>max</sub>. The threshold which maximised the sum of sensitivity and specificity is highlighted with the dark red circle. (D) Receiver operating characteristic curve of refractory intracranial hypertension detection with TIL<sub>median</sub>. The threshold which maximised the sum of sensitivity and specificity is highlighted with the dark red circle.







В







imputations. (**A**) Median component score of each ICP-treatment modality (Table 1) per each TIL<sub>24</sub> score. The histogram under the *x*-axis represents the relative frequency and count of each TIL<sub>24</sub> score in the population, and diagonal dashed line represents the TIL<sub>24</sub> score on both axes. If the sum of median item scores does not equal the corresponding TIL<sub>24</sub> score, this can be interpreted as high variability in the combination of simultaneously applied therapies at that TIL<sub>24</sub> score. (**B**) The repeated measures correlation coefficients ( $r_{rm}$ , from -1 to 1) are interpreted as the strength and direction of association between two variables after accounting for inter-patient variation. The component score of each item (Table 1, *x*-axis) was subtracted from the TIL<sub>24</sub> score (top row on *y*-axis) before calculating their  $r_{rm}$  values. (**C**) Linear mixed effects model coefficients ( $\beta_{LMER}$ ) are interpreted as the expected difference in the dependent variable (*y*-axis) associated with the given TIL<sub>24</sub> sub-item treatment (Table 1) after accounting for all other TIL<sub>24</sub> sub-items, time since ICU admission, and inter-patient variation.



**Fig 7. Relationship between TIL and TIL**<sup>(Basic)</sup>. Abbreviations: AUC=area under the receiver operating characteristic curve, ICU=intensive care unit, TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(Basic)</sup>=condensed TIL scale.<sup>8</sup> The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL<sub>24</sub>), maximum (e.g., TIL<sub>max</sub>), and median (e.g., TIL<sub>median</sub>) scores are described in the Methods. The 95% confidence intervals of information coverage were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. (**A**) Distribution of corresponding TIL<sup>(Basic)</sup><sub>24</sub> scores per each TIL<sub>24</sub> score. The values in each cell represent the percent of assessments at a given TIL<sub>24</sub> score (i.e., column) corresponding to a TIL<sup>(Basic)</sup><sub>24</sub> score (i.e., row). The vertical, dark red lines represent cut-offs across which the median corresponding TIL<sup>(Basic)</sup><sub>24</sub> score per TIL<sub>24</sub> score changes. (**B**) Distribution of corresponding TIL<sub>24</sub> scores, but the width of the points inside them demonstrates relative frequency across the TIL<sup>(Basic)</sup><sub>24</sub> scores. The grey, shaded zones represent the range of TIL<sub>24</sub> scores with corresponding median TIL<sup>(Basic)</sup><sub>24</sub> scores on the x-axis, as determined in panel (A). (**C**) The information of TIL<sub>24</sub>, TIL<sub>max</sub>, and TIL<sup>(Basic)</sup><sub>24</sub> (or TIL<sub>max</sub> and TIL<sup>(Basic)</sup><sub>max</sub> or TIL<sub>median</sub> and TIL<sup>(Basic)</sup><sub>median</sub>) divided by the entropy of TIL<sub>24</sub> (or TIL<sub>max</sub> or TIL<sub>median</sub>).

ICP-treatment	ing configurations f	TIL		uwTIL		TIL <sup>(Basic)a</sup>	PILOT⁵		TIL <sup>(1987)b</sup>	
modality	Sub-item	Score	Max	Score	Max	Score <sup>a</sup>	Score	Max	Score	Max
Positioning	Head elevation for ICP control or nursed	1	1	1	1	1	-	_	-	_
	flat (180°) for CPP									
Sedation and	management Sedation		5		3			5		4
neuromuscular	Low dose sedation	1	0	1	5	1	1	5	1	7
blockade	(as required for mechanical ventilation)									
	Higher dose sedation for ICP control (but not aiming for burst	2		2		2	1		1	
	suppression) High dose propofol or barbiturates for ICP control (metabolic suppression)	5		3		4	5		4	
	Neuromuscular	3	3	1	1	_	2	2	1	1
	blockade (paralysis)									
CSF drainage	CSF drainage volume		3		2			5		2
	Low (<120 ml/24h)	2		1		2	4		1	
	High (≥120 ml/24h)	3		2		3	5		2	
CPP management	Fluid loading for maintenance of	1	1	1	1	2	-	-	-	-
	cerebral perfusion Vasopressor therapy required for management of cerebral perfusion	1	1	1	1	2	2	2	-	-
Ventilatory	Hypocapnia for ICP		4		3			4		2
management	control (P <sub>a</sub> CO <sub>2</sub> [mmHg])									
	Mild (35≤P <sub>a</sub> CO <sub>2</sub> <40)	1		1		2	1		1	
	(33≤F <sub>a</sub> CO <sub>2</sub> <40) Moderate (30≤P <sub>a</sub> CO <sub>2</sub> <35)	2		2		3	2		1	
	Intensive $(P_aCO_2 < 30)$	4		3		4	4		2	
Hyperosmolar	Mannitol		3		2			3		6
therapy	administration ≤2g/kg/24h	2		1		2	2		3	
	>2g/kg/24h	3		2		3	3		6	
	Hypertonic saline	5	3	2	2	5	5	3		
	administration ≤0.3g/kg/24h	2	3	1	Z	2	3	3	-	-
	>0.3g/kg/24h	3		2		3	3			
Temperature control	Temperature control (T [°C])		5		3			5	-	-
Control	Fever control (>38 or spontaneous <34.5)	1		1			1			
	Cooling for ICP control (≥35)	2		2		3	3			
	Hypothermia (<35)	5		3		4	5			

#### Table 1. Scoring configurations for TIL and alternative scales

Surgery for intracranial hypertension	Intracranial operation for progressive mass lesion, NOT scheduled on admission Decompressive craniectomy	4 5	4	1	1	4	4 5	4	_	_
Maximum total	I possible score		38		21	4		38		15

Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, P<sub>a</sub>CO<sub>2</sub>=partial pressure of carbon dioxide in arterial blood, PILOT=Paediatric Intensity Level of Therapy scale,<sup>7</sup> T=body temperature in degrees Celsius, TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(1987)</sup>=original Therapy Intensity Level scale published in 1987,<sup>6</sup> TIL<sup>(Basic)</sup>=condensed TIL scale,<sup>8</sup> uwTIL=unweighted TIL scale in which sub-item scores are replaced by the ascending rank index within the item.

The TIL scale was developed by Maas *et al.*<sup>8</sup> For each calendar day, the highest score for each item was summed to derive the TIL score.

<sup>a</sup>TIL<sup>(Basic)</sup> is the maximum score (up to 4) among all administered sub-items over the calendar day. If no sub-items are administered on a given day, TIL<sup>(Basic)</sup>=0.

<sup>b</sup>PILOT scale<sup>7</sup> and TIL<sup>(1987)</sup> scale<sup>6</sup> scoring configurations have been adapted with minor adjustments to fit the items of TIL with a daily assessment frequency.

Summary characteristic	TIL validation population								
	Overall	TIL-ICP <sub>EH</sub>	TIL-ICP <sub>HR</sub>	р-					
	(n=873, 52 centres)	(n=837, 51 centres)	(n=259, 21 centres)	value <sup>c</sup>					
Age [years]	47 (29–62)	47 (29–62)	48 (30–62.5)	0.303					
Sex: Female	222 (25%)	213 (25%)	55 (21%)	0.078					
Baseline GCS (n <sup>a</sup> =822)				0.554					
Mild [13–15]	122 (15%)	115 (15%)	38 (16%)						
Moderate [9–12]	139 (17%)	133 (17%)	36 (15%)						
Severe [3–8]	561 (68%)	539 (68%)	170 (70%)						
Marshall CT (n <sup>a</sup> =710)				0.278					
No visible pathology (I)	17 (2%)	16 (2%)	6 (3%)						
Diffuse injury II	264 (37%)	248 (36%)	75 (35%)						
Diffuse injury III	93 (13%)	89 (13%)	22 (10%)						
Diffuse injury IV	16 (2%)	16 (2%)	3 (1%)						
Mass lesion (V & VI)	320 (45%)	312 (46%)	107 (50%)						
Six-month GOSE ( <i>n</i> <sup>a</sup> =761)				0.329					
(1) Death	199 (26%)	195 (26%)	54 (23%)						
(2 or 3) Vegetative or lower SD	182 (24%)	181 (25%)	63 (27%)						
(4) Upper SD	70 (9%)	66 (9%)	22 (9%)						
(5) Lower MD	122 (16%)	117 (16%)	44 (19%)						
(6) Upper MD	74 (10%)	71 (10%)	23 (10%)						
(7) Lower GR	56 (7%)	52 (7%)	14 (6%)						
(8) Upper GR	58 (8%)	55 (7%)	13 (6%)						
Baseline functional prognosis <sup>b</sup> [%] (/	n <sup>a</sup> =749)								
Pr(GOSE>1)	84.7 (63.5–94.9)	84.1 (62.1–94.7)	83.8 (66.9–94.0)	0.664					
Pr(GOSE>3)	53.9 (29.9–76.0)	53.1 (29.2–75.0)	52.4 (33.9–71.1)	0.287					
Pr(GOSE>4)	39.6 (20.6–59.6)	38.9 (19.8–58.3)	38.1 (22.6–54.6)	0.154					
Pr(GOSE>5)	21.1 (10.2–36.8)	20.7 (10.0–36.0)	19.3 (10.5–30.1)	0.037					
Pr(GOSE>6)	12.4 (5.9–20.8)	12.0 (5.8–19.9)	10.9 (5.8–17.2)	0.009					
Pr(GOSE>7)	4.8 (2.2–9.2)	4.7 (2.2–9.1)	5.3 (2.2–8.5)	0.415					
TIL <sub>max</sub>	10 (6–14)	10 (6–14)	10 (6–14)	0.577					
TIL <sub>median</sub>	5 (3–10)	5 (3–10)	5 (4–10)	0.826					
TIL <sub>24</sub> scores									
Day 1 ( <i>n</i> ª=852)	7 (4–11)	7 (4–11)	7 (5–10)	0.134					
Day 2 ( <i>n</i> <sup>a</sup> =839)	6 (4–10)	6 (4–10)	6 (4–10)	0.860					
Day 3 ( <i>n</i> <sup>a</sup> =819)	6 (3–9)	6 (3–9)	6 (4–9)	0.926					
Day 4 ( <i>n</i> <sup>a</sup> =787)	6 (3–10)	6 (3–10)	5 (4–10)	0.372					
Day 5 ( <i>n</i> <sup>a</sup> =761)	5 (3–10)	5 (3–10)	5 (3–10)	0.941					
Day 6 ( <i>n</i> <sup>a</sup> =733)	5 (2–9)	5 (2.5–9)	5 (3–10)	0.337					
Day 7 ( <i>n</i> ª=709)	5 (2–9)	4 (2–9)	5 (2–9)	0.425					

#### Table 2. Summary characteristics of study validation populations

Abbreviations: Baseline GCS=Glasgow Coma Scale at ICU admission, from 3 to 15, GOSE=GOS–Extended, GR=good recovery, ICP=intracranial pressure, ICP<sub>EH</sub>=end-hour ICP, ICP<sub>HR</sub>=high-resolution ICP, Marshall CT=Marshall computerised tomography classification, MD=moderate disability, Pr(GOSE>•)="probability of GOSE greater than • at six months postinjury" as previously calculated from the first 24 hours of admission,<sup>27</sup> SD=severe disability, TIL=Therapy Intensity Level scale, TIL<sub>24</sub>=TIL score of calendar day in ICU, TIL<sub>max</sub>=maximum TIL<sub>24</sub> over first week of ICU stay, TIL<sub>median</sub>=median TIL<sub>24</sub> over first week of ICU stay. Data are median (IQR) for numeric characteristics and *n* (% of column group) for categorical characteristics, unless

otherwise indicated. Units or numerical definitions of characteristics are provided in square brackets.

<sup>a</sup>Limited sample size of non-missing values for characteristic.

<sup>b</sup>Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical information in the first 24 hours of ICU stay, as described previously.<sup>27</sup>

<sup>c</sup>*p*-values, comparing patients in TIL-ICP<sub>HR</sub> sub-population to those not in TIL-ICP<sub>HR</sub> sub-population, are derived from with Welch's *t*-test for numeric variables and  $\chi^2$  contingency table test for categorical variables.

Category	Derived	Performance (95	% confidence interva	Case o	countsc	Previously	
	ranges	Sensitivity	Specificity	Accuracy	No	Yes	- proposed ranges <sup>d</sup>
Refractory intracranial	TIL <sub>max</sub> ≥14	68% (62–74%)	79% (77–81%)	77% (75–79%)	707	157	TIL <sub>max</sub> ≥11
hypertension <sup>a</sup>	TIL <sub>median</sub> ≥7.5	81% (77–87%)	72% (70–75%)	74% (72–76%)			-
Day of surgical ICP control <sup>b</sup>	TIL₂₄≥9	87% (83–91%)	74% (72–76%)	76% (74–77%)	4916	585	-
TIL <sup>(Basic)</sup> 24				72% (70–73%)			
(1) Basic ICU care	1≤TIL <sub>24</sub> ≤2				4932	568	1≤TIL <sub>24</sub> ≤3
(2) Mild	3≤TIL <sub>24</sub> ≤6				3294	2206	4≤TIL <sub>24</sub> ≤7
(3) Moderate	7≤TIL <sub>24</sub> ≤8				4709	791	8≤TIL <sub>24</sub> ≤10
(4) Extreme	TIL <sub>24</sub> ≥9				3919	1581	TIL <sub>24</sub> ≥11

 Table 3. Optimised ranges for TIL categorisation

Abbreviations: ICP=intracranial pressure, ICU=intensive care unit, TIL=Therapy Intensity Level scale,<sup>8,9</sup> TIL<sup>(Basic)</sup>=condensed TIL scale.<sup>8</sup> The numeric definition of each scale is listed in Table 1, and the calculation of daily (e.g., TIL<sub>24</sub>), maximum (e.g., TIL<sub>max</sub>), and median (e.g., TIL<sub>median</sub>) scores is described in the Methods. The 95% confidence intervals of performance metrics were derived from bootstrapping with 1,000 resamples of unique patients over 100 missing value imputations. <sup>a</sup>Refractory intracranial hypertension was defined as recurrent, sustained (i.e., of at least ten minutes) increases of ICP above 20 mmHg despite medical ICP management during ICU stay. This information was recorded by attending physicians in patient discharge summaries.

<sup>b</sup>If a decompressive craniectomy was performed as a last resort for refractory intracranial hypertension, each of the days following the operation were also considered days of surgical ICP control.

<sup>c</sup>For refractory intracranial hypertension, case counts represent the number of patients (with nonmissing values) without (i.e., No) and with (i.e., Yes) refractory intracranial hypertension. For day of surgical ICP control and TIL<sup>(Basic)</sup><sub>24</sub>, case counts represent the number of non-missing TIL assessments not in (i.e., No) and in (i.e., Yes) the given category.

<sup>d</sup>Thresholds were previously proposed by the interagency panel which developed TIL based on expert opinion.<sup>8</sup>